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ABSTRACT 
 
Mucosa-associated invariant T (MAIT) cells are a relatively recently discovered subset of 
unconventional T cells. In humans, MAIT cells are predominantly CD8+CD4- (CD8+) with a 
smaller CD8-CD4- (double-negative, DN) subset, and they are abundant in the peripheral 
blood, liver, and mucosal tissues. MAIT cells recognize riboflavin metabolites produced by a 
wide range of bacteria and fungi, and presented by the evolutionarily conserved major 
histocompatibility complex (MHC) class I-related (MR1) protein. Given the novelty of 
MAIT cells, this thesis had the overall aim of advancing the knowledge of their 
immunobiology and antimicrobial immune responses.  
In this thesis, we first established experimental platforms to study functions of MAIT cells in 
vitro, including activation, cytokine production, proliferation, cytotoxicity, as well as their 
ability to kill target cells. The established methodologies are versatile and can be adapted to 
answer a wide variety of MAIT cell-related questions. We next applied these experimental 
platforms to study MAIT cell responses to distinct riboflavin biosynthesis-competent 
microbes, and found them to differ in quality and quantity with the type and dose of microbe. 
We demonstrated that the TCR β chain composition and the expression of certain natural 
killer (NK)-cell associated receptors on MAIT cells shape their responses to TCR and innate 
cytokine stimulation, respectively, and thereby contribute to the functional 
compartmentalization of this cell population. In the third study, we dissected differences 
between CD8+ and DN MAIT cells with the aim of understanding the relationship between 
these subsets. CD8+ MAIT cells display superior functional capacity, consistent with their 
higher basal levels of co-stimulatory and cytotoxic molecules, and of classical effector 
transcription factors when compared with DN MAIT cells. Furthermore, DN MAIT cells 
accumulate during fetal development and their adult Vβ repertoire is a subset of that of CD8+ 
MAIT cells, suggesting that DN MAIT cells may derive from CD8+ MAIT cells in vivo. In 
the fourth study, we investigated MAIT cells in chronic hepatitis delta virus (HDV) infection. 
We found that MAIT cells are severely depleted from the peripheral blood of HDV-infected 
patients in comparison with chronic hepatitis B virus (HBV)-infected patients and healthy 
controls, and that MAIT cell loss is associated with the severity of liver fibrosis. Residual 
MAIT cells are activated, exhausted, and functionally impaired in response to TCR 
stimulation.  
Altogether, the findings in this thesis advance our understanding of human MAIT cells as 
functionally heterogeneous T cells that display differential response patterns to microbes and 
to innate cytokines, and that are markedly affected in hepatitis delta. At the same time, these 
findings have given rise to numerous new questions to be addressed in the rapidly expanding 
field of MAIT cell research in the years to come. 
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1 INTRODUCTION 
 
In a world abundantly populated by pathogens, the human body has developed multifaceted 
protective mechanisms that together constitute the immune system. This system counts on two 
main arms to ultimately fight infections. The innate immune system comprises anatomical, 
physiological, and inflammatory barriers, and uses innate immune cells to recognize 
structural motifs shared by many pathogens – the pathogen-associated molecular patterns 
(PAMPs) [1]. In this way, rapid responses against a broad range of pathogens can be mounted 
in an unspecific manner [1]. In contrast, the adaptive immune system relies on specialized 
cells that recognize unique pathogenic motifs, the antigens [1]. Such cells with a certain 
antigen specificity are relatively rare and need to expand upon antigen encounter in order to 
mount efficient responses [1]. Therefore, adaptive immune responses, although highly 
specific, take longer to develop [1].  
Classical (or conventional) T cells play a pivotal role in adaptive immunity. They express 
surface αβ T cell receptors (TCRs) that recognize peptide antigens in complex with molecules 
displayed on the surface of antigen-presenting cells (APCs) [2, 3]. The human TCR repertoire 
is generated by directed somatic recombination and is highly diverse. In addition, the antigen-
presenting molecules are encoded by genes of the major histocompatibility complex (MHC) 
that are highly polymorphic [2, 3]. This ensures that both the TCRs and the antigen-
presenting molecules can bind to virtually any pathogen-derived peptide [2, 3]. 
In between the fast and broad innate immune system and the slower but highly specific 
adaptive immune system, there is a group of T cells with both innate and adaptive 
characteristics. These cells are usually called unconventional or innate-like T cells [2, 3]. 
 
1.1 UNCONVENTIONAL T CELLS 
Unconventional T cells recognize antigens presented by antigen-presenting molecules 
encoded by genes that display a low degree of polymorphism [2, 3]. They are abundant in 
peripheral blood and/or tissues, and are able to quickly respond to antigenic challenges [2, 3]. 
Several types of human unconventional T cells have been described, including CD1-restricted 
T cells, HLA-E-restricted T cells, mucosa-associated invariant T (MAIT) cells (all of which 
are αβ T cells), and γδ T cells.  
1.1.1 Unconventional αβ T cells 
Group 1 (CD1a, CD1b, and CD1c) and group 2 (CD1d) molecules of the CD1 family can 
present a vast array of self and microbial lipid antigens to αβ T cells [2, 4-6]. Within the 
group 1 CD1-restricted T cells, CD1b-resticted T cells include, among others, the germline-
encoded mycolyl-reactive (GEM) [7] and the LDN5-like [8] T cells, which express conserved 
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TCRs and recognize glucose monomycolate, a mycobacterial glycolipid [7, 8]. CD1a- and 
CD1c- restricted T cells can also recognize mycobacterial lipid antigens [9-13]. In addition, 
CD1a-restricted T cells represent the majority of CD1-restricted autoreactive T cells [14, 15], 
and recognize a wide variety of endogenous antigens [2, 16].  
To date, group 2 CD1-restricted T cells, also called natural killer T (NKT) cells, are the most 
extensively studied T cells restricted by molecules of the CD1 family [6]. Type I NKT cells, 
or invariant NKT (iNKT) cells, express a semi-invariant TCR (Vα24-Jα18 paired with Vβ11 
in humans) [17, 18], and CD161 [19], a receptor expressed on natural killer (NK) cells and 
subsets of T cells [19-21]. iNKT cells recognize α-galactosylceramide (α-GalCer), among 
other lipids [2, 22], and represent approximately 0.1% of T cells in the peripheral blood of 
healthy adults [23]. In contrast, type II NKT cells are non-invariant and lack the conserved 
TCR Vα24 segment [2, 24]. These cells do not recognize α-GalCer and, to date, extensive 
investigation has been carried out on murine type II NKT cells that recognize sulfatide [2, 
25].  
Besides CD1-restricted T cells, there are also unconventional T cells restricted by the HLA-E 
molecule, which has been reported to bind peptides derived from MHC class I leader 
peptides, as well as from cytomegalovirus (CMV) and bacterial pathogens [2, 26-28]. 
This thesis focuses on human MAIT cells, which are described in detail in Section 1.2. 
1.1.2 Unconventional γδ T cells 
γδ T cells, duly named because of their surface expression of γδ as opposed to αβ TCRs, can 
be found in peripheral blood and tissues [2]. The most abundant γδ T cell population in 
human peripheral blood expresses a conserved γδ rearrangement and recognizes small, 
phosphorylated metabolites, which are generally called phosphoantigens and are produced by 
mammalian cells or microbes (e.g. 4-hydroxy-3-methyl-but-2-enyl pyrophosphate, or 
HMBPP, derived from bacteria) [2, 29]. Other γδ T cells recognize CD1a- and CD1d- lipid 
complexes [30-33], as well as stress-induced proteins, such as MHC class I polypeptide-
related sequence A (MICA) and UL16-binding protein (ULBP) [34, 35]. The panel of 
antigens and antigen-presenting molecules recognized by γδ T cells is very diverse and has 
been previously reviewed in detail [36, 37]. 
 
1.2 MAIT CELLS 
1.2.1 Towards the discovery of MAIT cells 
The semi-invariant TCR rearrangement characteristic of MAIT cells in humans, Vα7.2-Jα33, 
was identified for the first time in 1993 when Porcelli et al. [17] examined the TCRα chains 
of peripheral blood CD8-CD4- (double-negative, DN) T cells from healthy individuals [17]. 
Later in 1999, Tilloy et al. [38] reported that this TCR rearrangement defines a new cell 
population of DN and CD8αα T cells in humans with an effector memory phenotype 
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(CD45RAloCD45RO+) and preferential usage of the TCR Vβ2 or Vβ13 segments [38]. The 
homologous Vα19-Jα33 rearrangement was found in mice and cattle [38]. Already at this 
time, it was suggested that these cells were restricted by a distinct non-classical and β2-
microglobulin (β2m)-dependent antigen presenting molecule due to their absence in mice 
lacking β2m and their presence in humans and/or mice lacking MHC class I, MHC class II, 
CD1, and transporter associated with antigen processing (TAP) molecules [38]. In 2003, 
Treiner et al. [39] identified the MHC class I-related (MR1) protein as the restricting 
molecule of this cell population due to the absence of Vα19-Jα33 transcripts in MR1-
deficient mice [39]. The finding that T cells expressing the Vα7.2-Jα33 and Vα19-Jα33 
rearrangements were abundant in human gut biopsies and murine lamina propria, 
respectively, led these cells to be called mucosa-associated invariant T (MAIT) cells [39]. 
1.2.2 Evolutionary conservation of MR1 and MAIT cells 
The MR1 gene, discovered in 1995 [40], is believed to have been established 160 to 220 
million years ago in a common ancestor of placental and marsupial mammals [41]. MR1 and 
MAIT cells are present and highly conserved across mammals, and are found not just in 
humans and mice but also in non-human primates [42-44], cattle, sheep, bats, elephants, 
Tasmanian devils, and opossums [45, 46]. The degree of interspecies evolutionary 
conservation is high, as exemplified by the MR1 molecules from humans and mice, which 
are 90% and 89% identical in the amino acid sequences of their α1 and α2 domains, 
respectively [47]. Moreover, murine and human MAIT cells are highly cross-reactive to 
ortholog MR1 molecules [48, 49]. This suggests highly evolutionary conservation of the 
MR1 antigen presentation to MAIT cells process, and a fundamental role of the MAIT cell-
MR1 axis in the immune system.   
1.2.3 Identification of MAIT cells 
In 2009, Martin et al. [50] developed the monoclonal antibody (clone 3C10) that recognizes 
the human TCR Vα7.2 segment and showed that the Vα7.2-Jα33 gene rearrangement 
characteristic of MAIT cells was only found in Vα7.2+ cells expressing high levels of CD161 
[50]. Later in 2011, Le Bourhis et al. [49] reported that CD161 and interleukin (IL)-18 
receptor α (IL-18Rα) were co-expressed on MAIT cells [49]. Thus, co-expression of Vα7.2, 
and IL-18Rα or high levels of CD161 within the T cell compartment was adopted in the field 
to identify MAIT cells by flow cytometry. The identification of MAIT cell agonists [51, 52] 
(described in Section 1.2.6.3) led to the generation of fluorescent MR1 tetramers refolded 
with such compounds [51, 53]. As these reagents have become widely available to the 
research community, they are being adopted as a preferred tool for the identification of MAIT 
cells. In healthy adult individuals, the cell population identified using MR1 tetramers greatly 
overlaps with that defined as CD161hiVα7.2+ [51, 53, 54]. 
As MAIT cells are rare in common laboratory strains of mice [38], most studies on murine 
MAIT cells have relied on mouse models overexpressing MAIT cells (iVα19 and Vβ6 
transgenic mice, iVα19-Vβ6 double-transgenic mice, and more recently CAST/EiJ congenic 
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mice) [50, 55, 56]. The study of murine MAIT cells has been hampered by the lack of a 
Vα19-specific antibody, but has recently advanced through the development of murine MR1 
tetramers [53, 57]. 
1.2.4 MAIT cell development and phenotype  
Like NKT cells, MAIT cells develop in the thymus [38, 50], where they are selected by 
MR1-expressing CD8+CD4+ (double-positive, DP) thymocytes [58]. Two studies [59, 60] 
initially alluded to this through the detection of high levels of endogenous MR1 in mouse and 
human DP thymocytes [59, 60]. With the use of transgenic mouse models and thymic organ 
cultures, Seach et al. [58] went on to demonstrate an indispensable and non-redundant role of 
MR1-expressing DP thymocytes in MAIT cell selection in the thymus, whereas thymic B 
cells, dendritic cells (DCs), and macrophages were not essential for this process [58].  
In the thymus and cord blood, human MAIT cells display a CD45RA+CD45RO- naïve 
phenotype [50, 61, 62], whereas adult peripheral blood MAIT cells are CD45RA-
CD45RO+CD28+CCR7-CD62L- effector memory cells [38, 50, 61] (Figure 1). Cord and 
peripheral blood MAIT cells are predominantly CD8+CD4- (CD8+) and DN with minor CD8-
CD4+ (CD4+) cells. The thymus, however, contains CD4+, CD8+, and DP MAIT cells [50, 
63]. Koay et al. [63] proposed a three-stage pathway for MAIT cell development in the 
thymus consisting of CD161-CD27- cells (stage 1, predominantly DP and CD4+ in the 
thymus), CD161-CD27+ (stage 2, mostly DP, CD4+ and CD8+ in the thymus), and 
CD161+CD27pos-lo cells (stage 3, predominantly CD8+ and DN in the thymus) [63]. While 
stage 1 MAIT cells are exclusively present in the thymus, stage 2 MAIT cells are also 
detected in cord and peripheral blood samples from young children, albeit at lower levels, but 
they are absent in adult peripheral blood [63]. Stage 3 MAIT cells are rare in the thymus and 
predominate in cord and peripheral blood [63] (Figure 1). Importantly, and in contrast to cord 
and peripheral blood, MAIT cells in the thymus predominantly lack the expression of CD161 
and IL-18R [61, 63], and are only functional at stage 3 [63]. Stage 3 thymic MAIT cells 
respond to mitogen stimulation at lower levels than their extra-thymic counterparts, which 
suggests that the process of MAIT cell functional maturation occurs extra-thymically [63].   
MAIT cells in the thymus and cord blood exclusively express the CD8αβ co-receptor [62, 
63], whereas those in adult peripheral blood can express either CD8αβ or CD8αα [50, 62, 63] 
(Figure 1). Remarkably, CD8αα expression is mostly restricted to the MAIT cell population 
[62, 64]. CD161hiCD8αβ+ and CD161hiCD8αα+ T cells share similar phenotypic and 
functional characteristics, and CD161hiCD8αα+ T cells could be derived in vitro from 
CD161hiCD8αβ+ T cells [62]. This observation, together with the exclusive expression of 
CD8αβ among CD8+ MAIT cells in the cord blood and thymus [62, 63], suggests that 
CD8αα+ MAIT cells may derive from CD8αβ+ MAIT cells in vivo. 
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Figure 1. Phenotype and frequency of human MAIT cells in the thymus, cord blood, and adult peripheral 
blood. Expression levels of CD27 in S3 are abbreviated as pos (positive) and lo (low). S, stage. 
Thymic MAIT cells express the transcription factors promyelocytic leukemia zinc finger 
(PLZF or zinc finger and BTB domain containing 16, ZBTB16), retinoid-related orphan 
receptor (ROR) γt, and T box transcription factor 21 (TBX21 or T-bet) at gradually 
increasing levels from stage 1 to stage 3 [63]. In adult peripheral blood, MAIT cells express 
PLZF, likely responsible for their effector memory phenotype, and RORγt [50, 61, 65, 66, 
paper SII], a T helper (Th) 17 cell-associated transcription factor [67]. Adult circulating 
MAIT cells also express T-bet, Helios (or IKAROS family zinc finger 2, IKZF2), and 
eomesodermin (Eomes) at low, intermediate and high levels, respectively [65, paper SII]. 
Eomes and T-bet are reciprocally expressed by memory and effector CD8+ T cells [68], 
whereas Helios expression has been associated with T cell activation and proliferation [69]. 
In addition to the IL-18R, adult peripheral blood MAIT cells also express receptors for IL-12, 
IL-23, and IL-7 [61, 70, 71, paper SII]. Furthermore, they express the NK cell receptor 
NKG2D and CD26 [61], which is a dipeptidase and co-stimulatory molecule [72]. 
Interestingly, MAIT cells express high levels of the multidrug resistance protein 1 (MDR1, 
also known as ATP-binding cassette sub-family B member 1 (ABCB1)) [61], which is a 
multidrug efflux protein [73, 74]. Figure 2 summarizes the MAIT cell phenotype in the 
peripheral blood of healthy adult individuals.  
MAIT cells have also been studied in second-trimester fetal tissues, including the thymus, 
secondary lymphoid organs (spleen and mesenteric lymph nodes, MLNs), and peripheral 
organs (liver, lung, and small intestine) [75]. Fetal CD8αα+ and IL-18Rα+ MAIT cells, which 
display a more mature (effector memory) CD45RO+CD62L-PLZFhi phenotype than their 
negative counterparts, are preferentially enriched in the peripheral organs [75]. MAIT cells in 
the peripheral fetal organs are also more functional following bacterial stimulation than those 
in the secondary lymphoid organs and in the thymus [75]. This is consistent with the notion 
that functional maturation occurs outside the thymus [63], and suggests that MAIT cell 
maturation occurs in the fetus prior to bacteria exposure and establishment of the commensal  
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Figure 2. Phenotype of peripheral blood MAIT cells in healthy adult individuals. Expression levels are 
abbreviated as hi (high), int (intermediate), lo (low), and var (variable). 
microflora. Considering that cord blood MAIT cells are naïve, this may suggest the existence 
of two distinct MAIT cell subsets in adult individuals: a tissue-resident and non-recirculating 
effector memory MAIT cell subset established before birth, and a naïve MAIT cell subset 
that will mature after birth [76]. 
In the thymus and cord blood, MAIT cells are found at relatively low levels [50, 63] (Figure 
1). While thymic MAIT cell levels remain low and stable over time [63], the peripheral blood 
MAIT cell population gradually expands until 20-40 years of age, after which it contracts 
[77-79]. Peripheral blood MAIT cells reach frequencies approximately ten times higher than 
those in the thymus and cord blood [63], ranging between 1 and 10% of the total circulating T 
cells [50, 61] with high inter-individual variability [77, 78]. The levels of CD8+ and CD4+ 
MAIT cells inversely decrease and increase with age, respectively, and women of 
reproductive age (15 to 50 years old) were reported to have significantly more MAIT cells 
than men [77, 78]. Notably, while MAIT cells represent only a minor fraction (≈ 10%) of the 
CD161hiCD8α+ T cell pool in cord blood, they cover the vast majority of these T cells (≈ 
90%) in adult individuals [62]. 
1.2.5 MAIT cell tissue localization 
Adult peripheral blood MAIT cells express a distinct combination of chemokine receptors 
(Figure 2) that mediate their trafficking to peripheral tissues (Figure 3). This includes the 
expression of CCR6 and CXCR6 [61], liver-homing chemokine receptors [80-82], as well as 
α4β7 [39] and intermediate levels of CCR9 [61], receptors involved in lymphocyte migration 
to the gut [83-85]. Indeed, MAIT cells are highly enriched in the liver, where they constitute 
15% to 50% of hepatic T cells [61, 70, 86-89] and represent the predominant T cell 
population expressing CD161 and CD56 [89]. They are also present at variable frequencies 
within the gut. In the small intestine, MAIT cells have been found in the duodenum (≈ 2% of 
T cells) [90], jejunum (≈ 60% of CD4- T cells) [53], and ileum (≈ 1.5% of T cells) [91], 
whereas in the large intestine they are present in the colon (≈ 10% of T cells) [87, 92], and in 
the rectum (≈ 2% of T cells) [93]. The expression of CXCR6 and CCR5 [61] also indicates 
their ability to traffic to the lungs [94] (≈ 2% of T cells in sputum and bronchoalveolar 
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lavage, and ≈ 4% of T cells in endobronchial biopsies) [95, 96] (Figure 3). MAIT cells have 
also been detected in the stomach (≈ 2.5% of T cells) [97], the endometrium and cervix (≈ 1 
to 2% of T cells) [65], and the skin [98, 99]. Transcripts for the MAIT cell TCR were also 
detected in the kidneys, ovaries, and prostate [100]. In contrast, MAIT cells are rarely found 
in lymph nodes [61] due to their lack of CD62L and CCR7 expression [61, 101-104].  
              
Figure 3. Tissue distribution of MAIT cells in healthy adult individuals. Approximate frequencies of MAIT 
cells within total CD3+ cells are indicated, except for MAIT cells in the jejunum where the frequency (*) has been 
determined within CD3+CD4- cells. 
1.2.6 Antigen presentation to MAIT cells 
1.2.6.1 MR1 
MR1 is a non-polymorphic gene located on chromosome 1 in humans [40], similar to the 
CD1 gene [105], and outside of the MHC located on chromosome 6 [106]. Surprisingly, 
however, the MR1 molecule shares higher homology in its α domains with classical MHC 
class I (MHC-Ia) molecules compared with other non-classical MHC class I (MHC-Ib) 
molecules [40]. 
Four human MR1 isoforms have been identified that are generated through alternative 
splicing and are denoted MR1A to MR1D [47]. MR1A corresponds to the full-length protein 
that was originally discovered, and is made up of 341 amino acids and all of the structural 
domains of a MHC-Ia molecule: namely a signal peptide, three extracellular domains (α1 and 
α2, which form the ligand-binding pocket, and α3, which interacts with β2m), a 
transmembrane domain, and a cytoplasmic domain [40, 47, 52, 107, 108]. The other three 
isoforms lack the α3 domain [47], and the MR1C transcript also lacks the transmembrane 
domain, thereby potentially encoding a soluble protein [47]. Similar to MR1A, MR1B is a 
functional antigen-presenting molecule capable of MAIT cell activation that is expressed on 
the cell surface as a homodimer and in the absence of β2m [47, 109, 110]. 
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Although human MR1 transcripts are ubiquitously expressed [40, 47, 110], basal surface 
expression of MR1 (i.e., at steady state) has been difficult to detect on non-MR1 transfected 
cells [46, 59, 110-113], and reports on its intracellular location are controversial. Some 
studies suggest that MR1 is predominantly retained in a pre-Golgi compartment, namely the 
endoplasmic reticulum (ER) [108, 114], in a ligand-receptive and incompletely folded state 
with no β2m association [114]. In contrast, others have reported that MR1 is located both in 
the ER, and in late endosomes and lysosomes where it associates with β2m [115, 116]. MR1 
predominantly binds to soluble ligands (described in Section 1.2.6.3) in the ER via the 
formation of a Schiff base (covalent bond) between the positively charged amino group of 
lysine-43 (K43) and the ligand, which in turn neutralizes the positive charge in K43 [114]. 
This promotes complete folding of MR1, association of MR1 with β2m [114], and egress of 
the MR1-β2m-ligand complex, which leads to its rapid upregulation on the cell surface [114, 
115]. The ternary complex is then internalized and degraded in late endosomes and 
lysosomes [114], with only a small fraction of the internalized MR1 reportedly exchanging 
ligands and recycling back to the cell surface [114]. In addition to the ER, Harriff et al. [115] 
reported that endocytic compartments can also function as a source of MR1 molecules 
available to bind soluble ligands before translocation to the cell surface [115]. Differences 
between the aforementioned studies both at steady state and in the presence of soluble ligands 
may be due to the presence [108, 115, 116] or absence [114] of soluble MR1 ligands in the 
culture medium, the effect of MR1 overexpression [108, 114, 116] and of molecular tags in 
MR1 trafficking [115, 116], and the cell types used in the assays [117]. 
A few MR1 molecules can leave the ER and bind to soluble ligands directly on the cell 
surface [114]. This is in agreement with the capacity that fixed APCs have to activate MAIT 
cells in the presence of ligand-producing microbes [49], and may represent an important 
pathway for presentation of ligands that may not be able to reach the ER or endosomes in 
sufficient concentrations to bind to MR1 [3]. Nonetheless, the contribution of surface loading 
to the overall ligand presentation by MR1 is probably limited in most circumstances [114]. 
Microbe-associated ligands (i.e., ligands from intracellular or phagocytosed microbes) appear 
to be loaded and presented by MR1 via endosomes through a different pathway than that 
utilized for soluble ligands [113, 115]. In support of this notion, the trafficking molecules 
involved in these processes were reported to be different [115], and inhibitors of phagocytosis 
and endolysosomal acidification decreased MAIT cell activation in response to ligand-
producing microbes but not to microbial supernatants [49, 113].  
MR1 surface expression increases upon ligand availability, and its surface expression was 
shown to depend on nuclear factor-kB (NF-kB)-mediated activation of APCs [113]. In 
addition, toll-like receptor (TLR)-mediated stimulation of APCs can also increase MR1 
surface expression [113, 118].  
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1.2.6.2 MAIT cell TCR 
Most MAIT cells express the TCRα chain defined by the Vα7.2-Jα33 rearrangement [38, 53], 
whereas a minority expresses either Vα7.2-Jα12 or Vα7.2-Jα20 instead [53, 100]. Overall, the 
Jα12 and Jα20 sequences are very similar to Jα33, and, importantly, they retain the tyrosine-
95 (Y95) residue within the CD3Rα loop, which is crucial for MAIT cell activation (as 
described in Section 1.2.6.4) [53]. These TCRα chains predominantly pair with Vβ2 or 
Vβ13.2, although additional Vβ diversity has been described for MAIT cells with the Vα7.2-
Jα33 rearrangement [38, 53, 100, 119].  
1.2.6.3 MR1 ligands & MAIT cell agonists and antagonists 
In 2012, a seminal paper by Kjer-Nielsen et al. [52] described the first MR1 ligands with the 
capacity to activate MAIT cells. These were compounds derived from the riboflavin (or 
vitamin B2) biosynthesis pathway known as ribityl lumazines: reduced 6-hydroxymethyl-8-
D-ribityllumazine (rRL-6-CH2OH), 7-hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-7-
OH), and 6,7-dimethyl-8-D-ribityllumazine (RL-6,7-diMe) [52]. Subsequently, the 
pyrimidines 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) and 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) were identified as highly potent 
MAIT cell agonists [51]. These pyrimidines are formed by a non-enzymatic reaction between 
5-amino-6-D-ribitylaminouracil (5-A-RU), a riboflavin precursor, and either methylglyoxal 
or glyoxal [51], two ubiquitous molecules produced during several metabolic pathways in 
microbes or humans, including glycolysis [3, 120]. Both 5-OE-RU and 5-OP-RU are very 
unstable, especially in acidic aqueous medium, and they quickly undergo dehydration to form 
the stable ribityl lumazines [51]. However, they can be captured and stabilized by MR1, and 
then function as potent MAIT cell activating antigens [51].  
Riboflavin is produced by plants, as well as by bacteria and fungi [121, 122]. Therefore, 
MAIT cells can be activated in an MR1-dependent manner by microorganisms that possess 
the riboflavin biosynthesis pathway, including Escherichia, Pseudomonas, Klebsiella, 
Lactobacillus, Staphylococcus, Mycobacteria, and Salmonella species of bacteria, and 
Candida and Saccharomyces species of fungi, but not by microbes that lack the ability to 
produce riboflavin, such as Enterococcus faecalis, Streptococcus group A, and Listeria 
monocytogenes [49, 52, 123]. Interestingly, because MR1 ligands are secreted and diffusible, 
it has been hypothesized that MAIT cells may sense microbial infections across mucosal 
membranes [52]. As mammals are unable to produce riboflavin, MAIT cell recognition of 
microbial riboflavin derivatives provides another basis for immune-mediated self vs. non-self 
discrimination [124].   
A group of MR1 ligands with the capacity to upregulate MR1 surface expression without 
activating MAIT cells has been described. These compounds are MAIT cell antagonists, 
which inhibit MAIT cell activation by competing with MAIT cell agonists for the MR1 
binding pocket [3], and they derive from folic acid [52, 125, 126], a constituent of the diet 
and of culture media such as RPMI-1640 [3, 52]. The first MAIT cell antagonist identified 
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was 6-formyl pterin (6-FP) [52], which is spontaneously generated by the photodegradation 
of folic acid [127]. Later on, acetyl-6-FP (Ac-6-FP), an acetylated analog of 6-FP, and two 
other variants of 6-FP, 2-acetylamino-4-hydroxy-6-formylpteridine dimethyl acetal and 2-
acetylamino-4-hydroxy-6-formylpteridine, were described as more potent MAIT cell 
antagonists that upregulate MR1 to a greater extent than 6-FP [126].  
The identification of MR1 ligands has made possible the generation of MR1 tetramers loaded 
with rRL-6-CH2OH [53], 5-OE-RU, and 5-OP-RU [51], which efficiently stain all human 
MAIT cells, contrarily to the MR1 tetramers loaded with 6-FP and Ac-FP [125]. MR1 
tetramers loaded with 5-OP-RU (and with 6-FP for use as a negative control) are presently 
used to specifically detect and study MAIT cells. Furthermore, an MR1 ligand analogue of 5-
OP-RU that displays greater stability in water has been synthesized, and it is capable of MR1 
surface upregulation and MAIT cell activation [128]. More recently, a new panel of MR1 
ligands has been identified that includes drugs, drug metabolites, and drug-like molecules, 
such as diclofenac (DCF) and salicylates, with differential capacities to upregulate MR1 and 
activate or inhibit MAIT cells [129]. Overall, the MR1 ligands identified to date suggest that 
MR1 can accommodate a heterogeneous panel of compounds, which opens a window of 
possibilities for the modulation of MAIT cell activity in vitro and in vivo [129]. To date, no 
endogenous MR1 ligands have been identified.  
1.2.6.4 MAIT cell TCR recognition of MR1-ligand complexes 
The MAIT cell agonists 5-OE-RU and 5-OP-RU and the antagonists 6-FP and Ac-6-FP 
covalently bind to MR1 via the formation of a Schiff base with the K43 residue of MR1, 
which demonstrates a strong association between MR1 and the ligand [51, 52, 125]. Schiff 
base formation triggers the molecular alterations necessary for MR1 to traffic to the cell 
surface (as described in Section 1.2.6.1) [114], and is, therefore, essential for efficient MR1 
surface expression [3]. In agreement with this, the ribityl lumazine RL-6-Me-7-OH, DCF and 
its metabolite 5-hydroxy DCF (5-OH-DCF), which establish multiple contacts with MR1 
without the formation of a Schiff base [3, 51, 129], are less potent inducers of MR1 surface 
upregulation than 5-OP-RU [129].  
The MAIT cell activating ribityl lumazines and pyrimidines structurally resemble 6-FP but 
contain an extra ribityl moiety that allows direct contact with the MAIT cell TCR [51, 52, 
130]. This occurs through formation of a direct hydrogen bond between the ribityl moiety and 
the Y95 residue located in the CDR3α loop of the MAIT cell TCR, and was uniformly 
demonstrated for the activating antigens rRL-6-CH2OH, RL-6-Me-7-OH, 5-OE-RU, and 5-
OP-RU [51, 130, 131]. Interestingly, the importance of Y95 was first hinted before the 
identification of any MR1 ligands, when Reantragoon et al. [132] studied the recognition of 
human MR1 by the MAIT cell TCR through site-directed mutagenesis of several residues in 
the TCRα and β chains [132]. In contrast, recognition of DCF and 5-OH-DCF does not 
involve the formation of a hydrogen bond with the Y95 residue of the TCR [129]. 
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1.2.7 MAIT cell effector functions 
1.2.7.1 Upregulation of activation markers and production of cytokines 
MAIT cells respond to riboflavin-producing microbes through the upregulation of the 
activation markers CD69 and CD25 (or IL-2Rα chain) [49, 92, 93, 133] and the secretion of 
cytokines. Peripheral blood MAIT cells produce high levels of the Th1 cytokines interferon 
(IFN) γ and tumor necrosis factor (TNF) [49, 53, 61, 70, 75, 92, 93, 123, 134] (Figure 4), but 
little or no Th17 cytokines, including IL-17A and IL-22 [61, 75, 92, 93], despite the 
constitutive expression of the transcription factor RORγt [61, 65, paper SII]. They can, 
however, produce IL-17A following stimulation with phorbol myristate acetate 
(PMA)/ionomycin [61, 89], albeit at lower levels than liver MAIT cells [89], which represent 
the main IL-17-producing T cell population in that organ [89]. Liver MAIT cells also produce 
IFNγ following microbial stimulation [70, 89]. In contrast, MAIT cells from the female 
genital tract (endometrium and cervix) display a distinct Th17 cytokine profile in response to 
microbes, with higher production of IL-17A and IL-22 and lower production of IFNγ and 
TNF than peripheral blood MAIT cells [65]. 
Production of the Th2 cytokines IL-4, IL-5, IL-9, and IL-13, as well as of the T regulatory 
(Treg) cytokine IL-10 by peripheral blood and liver MAIT cells is low or non-existent [61, 
89, 135-137]. However, MAIT cells in adipose tissue were reported to produce high levels of 
IL-10 following PMA/ionomycin stimulation [135]. Also, IL-2 expression by liver and blood 
MAIT cells was only detected after stimulation with PMA/ionomycin [53, 61, 89] or with 
superantigens [138]. The latter are potent exotoxins secreted by bacteria including 
Streptococcus pyogenes and Staphylococcus aureus that cross-link TCRs on a significant 
proportion of T cells and MHC class II molecules on APCs, resulting in massive activation of 
these cells and release of pro-inflammatory mediators [139, 140].  
Activated MAIT cells can also produce granulocyte-macrophage colony-stimulating factor 
(GM-CSF), which is involved in MAIT cell cross-talk mechanisms with other cell types [141, 
142]. The combined production of IFNγ, TNF, and GM-CSF by MAIT cells in vitro was 
shown to mediate survival, activation, and differentiation of neutrophils into APC-like cells 
capable of both exogenous antigen processing and priming of conventional T cells, ultimately 
resulting in T cell activation and proliferation [141]. In another study, GM-CSF produced by 
MAIT cells induced differentiation of monocytes into DCs in vitro and in a murine model of 
pulmonary infection in vivo. In this mouse model, DCs were in turn involved in the 
recruitment of activated CD4+ T cells to the site of infection [142]. In addition, activated 
human MAIT cells have recently been shown to induce maturation of DCs in vitro in an 
MR1- and CD40 ligand (CD40L)- dependent manner [143]. Altogether, this indicates that 
MAIT cells can link mechanisms of innate and adaptive immunity, which contributes to their 
involvement in microbial infections.  
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1.2.7.2 Degranulation and killing 
Following microbial stimulation, MAIT cells not only produce cytokines but also degranulate 
and kill infected target cells (Figure 4). Resting peripheral blood MAIT cells express 
granzyme (Grz) A, variable levels of granulysin (Gnly), low levels of perforin (Prf), and 
virtually no GrzB [133, 144, paper SII] (Figure 2). Prf is a membrane pore-forming protein 
that ultimately allows release of Grz and Gnly molecules into the cytoplasm [145]. While 
GrzB potently and rapidly induces cell death by apoptosis [145], the cytotoxic capacity of 
human GrzA is minimal [145, 146]. Gnly is an antibacterial protein that kills intracellular 
bacteria by damaging their membranes [145, 147]. At baseline conditions, Prf is co-expressed 
with GrzA and Gnly [paper SII], and GrzA co-localizes with CD107a [144]. This indicates 
that MAIT cells contain a readily available pool of cytotoxic molecules that can be rapidly 
released upon degranulation. Following activation, MAIT cells degranulate as indicated by 
the increased expression of CD107a [70, 133, 134, 144, paper SII], lose GrzA and Gnly [144, 
paper SII], and upregulate GrzB and Prf [61, 144, paper SII]. Importantly, the 
CD107a+GrzAlo MAIT cells concomitantly express GrzB and Prf, which indicates that MAIT 
cells exocytose these molecules upon stimulation [paper SII] (Figure 4). This in turn 
associates with their capacity to kill target cells in vitro, as demonstrated by the release of the 
cytoplasmic protein lactate dehydrogenase (LDH) in the supernatant of MAIT cell co-
cultures with infected target cells [133], the fluorometric assessment of T lymphocyte antigen 
specific lysis (FATAL) assay [144, 148], and the flow cytometric evaluation of the levels of 
dead target cells [paper SII]. Importantly, resting MAIT cells are not efficient killer cells due 
to their lack of GrzB and lower levels of Prf at baseline conditions, when compared with 
conventional CD8+ T cells [144, paper SII]. 
                  
Figure 4. Summary illustration of the effector functions of peripheral blood MAIT cells following 
stimulation with riboflavin biosynthesis-competent microbes. Following microbial stimulation, MAIT cells are 
able to produce IFNγ and TNF, as well as to degranulate, release GrzA, GrzB, Gnly, and Prf, and kill target cells. 
MAIT cell responses result from TCR-antigen-MR1 interactions and from the direct effect of APC-derived innate 
cytokines, such as IL-12 and IL-18, on MAIT cells.  
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1.2.7.3 Proliferation 
Peripheral blood MAIT cells are also able to proliferate in vitro in response to microbial 
stimulation [75, 144, paper SII], and this occurs despite their lack of basal Ki-67 expression 
ex vivo [61, 144]. MAIT cells upregulate Ki-67 after microbial stimulation, and cells that 
have proliferated retain their cytolytic profile with high levels of GrzB and Prf [144]. 
As MR1 is ubiquitously expressed [40, 47, 110], the ability of many different cell types to 
function as APCs in studies of human MAIT cell responses to microbial stimulation has been 
demonstrated. These include monocytes [49, 61, 138, 149], macrophages [70, 149], DCs 
[123, 149, 150], B cells from the blood [134] and liver [70], and epithelial cells from the bile 
ducts [70] and lungs [123, 150]. 
1.2.7.4 MR1-dependency of MAIT cell responses to microbes 
The MAIT cell effector functions in response to microbial stimulation described above can 
result from TCR-antigen-MR1 interactions (MR1-dependent responses) and from the direct 
effect of cytokines produced by APCs, such as IL-12 and IL-18, on MAIT cells (MR1-
independent responses) (Figure 4). Some functions, including the production of IFNγ, TNF, 
IL-17 [49, 65, 70, 89, 93, 123, 134], degranulation, loss of GrzA, killing, and proliferation 
[70, 133, 144, paper SII], are more MR1-dependent than others, such as the upregulation of 
GrzB and Prf, and the production of IL-22 [65, 144, paper SII]. Previous studies [88, 151] 
have shown that the short-term IFNγ production by peripheral blood and liver MAIT cells in 
response to riboflavin biosynthesis-competent Escherichia coli was predominantly MR1-
dependent, whereas the long-term response was both MR1-dependent and –independent [88, 
151]. In contrast, the response to riboflavin biosynthesis-incompetent E. faecalis was solely 
MR1-independent, resulting from the action of IL-12 and IL-18 on MAIT cells [88, 151]. 
1.2.7.5 MR1-independent MAIT cell responses to innate cytokines 
MAIT cells express IL-12R and IL-18R [49, 70, 71], the latter at higher levels than 
conventional CD8+ T cells, and can produce IFNγ in response to IL-12 and IL-18 in a process 
independent of MR1 and TCR signaling [151].  
Other cytokines can also exert varying effects on MAIT cells. In the absence of microbial 
stimulation, IL-15 in synergy with IL-18 and/or IL-12 activates peripheral blood MAIT cells 
to produce IFNγ and GrzB and to upregulate CD69 [149, 152, 153]. Remarkably, MAIT cells 
constitute the predominant IFNγ-producing T cell population in response to IL-15 stimulation 
[152]. On the other hand, IL-7 induces production of GrzB and enhances the expression of 
Prf and the transcription factors PLZF, RORγt, T-bet, Eomes, and Helios without 
concomitant production of IFNγ, TNF, or IL-17A [paper SII]. Following suboptimal 
stimulation with E. coli, both IL-15 and IL-7 augment the expression of cytokines and 
cytolytic molecules [152, paper SII], thereby also increasing the killing capacity of MAIT 
cells [paper SII]. Notably, IL-7 or the combination of IL-1β and IL-23 were also shown to 
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enhance IFNγ and IL-17 production by liver MAIT cells following anti-CD3/CD28 TCR-
mediated stimulation [89].  
In a recent study, Shaler et al. [138] studied the response of MAIT cells to bacterial 
superantigens. MAIT cells respond to staphylococcal enterotoxin B (SEB) by producing 
IFNγ, TNF, and IL-2 in a process independent of MR1, but dependent on HLA class II, IL-
12, and IL-18 [138]. Notably, the MAIT cell response to SEB was more potent than that 
mounted by iNKT, γδ, and conventional T cells [138]. 
The capacity of MAIT cells to undergo cytokine-mediated activation also allows them to 
respond to viruses in vitro [149, 154]. MAIT cells respond to dengue virus, influenza virus, 
and hepatitis C virus (HCV) by producing IFNγ and GrzB [149, 154]. IL-12, IL-18, and IL-
15 blocking experiments showed that the MAIT cell IFNγ production predominantly depends 
on IL-12 and IL-18, IL-18 alone, and IL-18 and IL-15, in response to dengue virus, influenza 
virus, and HCV, respectively [149, 154]. IFNα and IFNβ, both key players in anti-viral 
immune responses [155], also activate MAIT cells in vitro when in combination with IL-12 
or IL-18, and further contribute to the MAIT cell responses to HCV [149]. Importantly, 
activated MAIT cells inhibit HCV replication in vitro via IFNγ production [149, 154]. 
The activation of MAIT cells by TLR agonists, which may occur during microbial or viral 
stimulations, is also driven by cytokines in an MR1-independent manner [88, 151]. Agonists 
for TLR3, TLR4 (lipopolysaccharide, LPS) and TLR8 (single-stranded RNA40) activate 
peripheral blood and liver MAIT cells to produce IFNγ via IL-12 and IL-18 [88, 149, 151].  
1.2.7.6 Regulation and modulation of MAIT cell effector functions 
The interplay between MAIT cells, APCs, microbes, and cytokines indicates the existence of 
several levels at which MAIT cell responses can be regulated. Slichter et al. [153] 
demonstrated that cytokines alone, but not TCR stimulation alone, are sufficient to induce 
MAIT cell production of IFNγ and GrzB, and that both types of stimuli synergize to induce 
potent MAIT cell responses [153]. This is consistent with the low MAIT cell responses 
reported following anti-CD3/28 stimulation alone [53, 61, 89], and with the notion that the 
production of inflammatory mediators is tightly regulated in order to prevent inflammatory 
responses to commensal riboflavin biosynthesis-competent microorganisms. 
The expression of CD161 can modulate MAIT cell responses although its 
immunomodulatory effects are, thus far, controversial. Upon anti-CD3/28 TCR stimulation, 
ligation of CD161 decreased the expression of activation markers and cytokines but did not 
affect the cytolytic ability of MAIT cells in one study [133], whereas, in another [119], it 
increased the expression of cytokines. More studies are warranted to clarify the modulatory 
role of CD161 in MAIT cell responses. 
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1.2.8 Atypical MAIT cells and other MR1-restricted T cells 
The MAIT cell population was recently extended after the identification of MAIT cells 
capable of recognizing not only 5-OP-RU but also 6-FP or Ac-6-FP [156]. Moreover, non-
classical MR1-restricted T cells (i.e., T cells restricted by MR1 but with TCR rearrangements 
different from those described for MAIT cells) have been reported to recognize riboflavin or 
folate metabolites [156], respond to Streptococcus pyogenes (a riboflavin biosynthesis-
incompetent microbe) in an MR1-dependent manner (which suggests that MR1 can present 
microbial activating ligands other than riboflavin metabolites) [157], or respond to non-
microbial antigens [158]. Altogether, these findings broaden the definition of MR1-restricted 
T cells to include other cells that may not express the TCR Vα7.2 segment and/or recognize 
microbial riboflavin metabolites.  
1.2.9 MAIT cell antimicrobial role in vivo 
The high evolutionary conservation of the MAIT cell-MR1 axis among mammals and the 
ability of MAIT cells to recognize intermediates of the riboflavin biosynthesis pathway, 
which is conserved among many different species of bacteria and fungi, suggest that MAIT 
cells play an essential role in host protection against microbes [159].  
1.2.9.1 Bacterial infections 
Studies using WT and MR1 knock-out (KO, MR1-/-) mice indicated that MAIT cells have a 
protective role in bacterial infections. A higher bacterial load was detected in the spleens of 
MR1-/- mice after infection with E. coli [49] and Mycobacterium abscessus [49], as well as in 
the lungs following infection with Mycobacterium bovis Bacillus Calmette-Guérin (BCG) 
[160]. Moreover, MR1-/- mice not only had a higher bacterial burden, but also succumbed to 
infections by Francisella tularensis [161] and Klebsiella pneumoniae [162] at a higher rate 
than WT mice. 
Examinations of MAIT cells in patients suffering from diverse bacterial infections have 
shown this cell population to be markedly affected. Levels of MAIT cells are lower in the 
peripheral blood but higher in the lungs of patients with active Mycobacterium tuberculosis 
infection [49, 123, 163, 164], which suggests recruitment of these cells to the site of infection. 
Interestingly, two studies showed that the decline in peripheral blood MAIT cells selectively 
occurs in patients with active infection, and not in those with latent infection [123, 163]. In 
cystic fibrosis (CF) patients, the levels of peripheral blood MAIT cells are also lower than in 
healthy controls [165]. This decline is associated with disease severity and more pronounced 
in CF patients infected with Pseudomonas aeruginosa [165].  
In addition to pulmonary infections, several studies have reported the involvement of MAIT 
cells in gastrointestinal infections. MAIT cell levels are reduced in the peripheral blood of 
Helicobacter pylori-infected volunteers, with no apparent recruitment to the gastric mucosa 
[97]. They are also decreased in the peripheral blood of Vibrio cholerae O1-infected children 
[166] and in volunteers who were orally challenged with an attenuated strain of Shigella 
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dysenteriae 1 [133]. Interestingly, in these studies, the presence of activated MAIT cells 
positively correlated with the development of V. cholerae- or S. dysenteriae- specific IgA 
antibodies, respectively [133, 166], suggesting that MAIT cells may be involved in protective 
antibody-mediated responses against enteric pathogens [159]. Consistent with these findings, 
Bennett et al. [167] have recently shown that supernatants from activated MAIT cells 
promote plasmablast differentiation, as well as IgA, IgG, and IgM antibody production in 
vitro [167]. The levels of CD8+ MAIT cells are also lower in the peripheral blood of 
Salmonella enterica serovar Typhi-infected volunteers who developed typhoid fever, but not 
in those who did not develop typhoid disease [168], again suggesting the involvement of 
MAIT cells in enteric infections.  
Analysis of MAIT cells in severely ill patients revealed that the levels of MAIT cells in 
peripheral blood are dramatically decreased in patients with bacterial infections, and the 
extent of decline is bigger in those with non-streptococcal infections [169]. Notably, the 
development of nosocomial infections was more likely to occur in patients with persistent 
MAIT cell depletion, in contrast to those where MAIT cell levels increased over time [169]. 
This suggests a protective role of MAIT cells in severe bacterial infections. Another study, 
however, showed that in peritoneal dialysis, patients who developed acute peritonitis caused 
by riboflavin biosynthesis-competent microbes have MAIT cell accumulation in the 
peritoneal cavity, where they produce IFNγ and TNF, and promote local inflammation [170]. 
More studies are thus warranted to ascertain the precise role of MAIT cells (protective, 
pathogenic, or modulatory) in the different types of bacterial infections. 
1.2.9.2 Fungal infections 
Several species of fungi, including Candida albicans and Saccharomyces cerevisiae, possess 
the riboflavin biosynthesis pathway and can activate MAIT cells in vitro [49, 52]. However, 
to date, the role of MAIT cells in fungal infections in either humans or in animal models has 
not been investigated.  
1.2.9.3 Parasitic infections 
So far only one study has investigated MAIT cells in parasitic infections. Mpina et al. [171] 
reported that following intradermal administration of a high dose of Plasmodium falciparum 
sporozoites to Tanzanian volunteers, peripheral blood MAIT cell levels decreased during 
early blood-stage parasitemia (11 to 18 days post-infection). Surprisingly, after treatment, 
MAIT cells rebounded and were maintained in levels higher than those initially measured up 
to several months post-infection [171].  
1.2.9.4 Viral infections 
Although viruses do not produce riboflavin metabolites, the MAIT cell compartment is 
markedly affected in several human viral diseases. MAIT cells were found to be depleted in 
the peripheral blood of patients infected with human immunodeficiency virus type 1 (HIV-1), 
as reported in numerous studies [86, 92, 93, 172-174]. These findings were confirmed by 
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studies at the mRNA and gDNA level of the presence of the Vα7.2-Jα33 rearrangement 
[174]. The decline in MAIT cell levels is not reverted with effective antiretroviral therapy 
(ART) [86, 92, 93, 172]. Interestingly, in perinatally HIV-1-infected children, CD8+ MAIT 
cells are also lost from the periphery, but gradually recover with ART [175]. In contrast to 
peripheral blood, the levels of MAIT cells in rectal mucosa and colon of HIV-1-infected 
patients seem relatively well preserved [92, 93], despite the selective loss of CD4+ MAIT 
cells in the rectal mucosa that is in agreement with the overall loss of rectal mucosal CD4+ T 
cells during HIV-1 infection [93]. In HIV-1/M. tuberculosis co-infection (both active or latent 
bacterial infections), the levels of CD161++CD8+ T cells in healthy individuals were detected 
at low levels similar to those detected in HIV-1 mono-infection [176].  
MAIT cells have also been studied in infections caused by dengue virus [149], influenza virus 
[149, 154], and human T-lymphotropic virus type 1 (HTLV-1) [177], a delta retrovirus that 
has been implicated in several neoplasms, inflammatory syndromes, and opportunistic 
infections [178]. In these viral infections, the levels of circulating MAIT cells are also 
decreased when compared with healthy controls [149, 154, 177]. Interestingly, in one study 
on patients with severe influenza infections, MAIT cells were found at similar levels in both 
healthy controls and patients that survived, but were markedly decreased in those who 
succumbed to the infection, suggesting that MAIT cells may play a protective role in human 
influenza [154].  
Furthermore, MAIT cells have also been shown to be involved in hepatitis. MAIT cell levels 
are decreased in the blood [86, 149, 179-182] and liver [86, 180] of chronic HCV-infected 
patients. While the decline in circulating MAIT cells in blood appears to be independent of 
the stage of liver fibrosis [179], their levels in the liver were found to inversely correlate with 
liver inflammation and fibrosis in one study [180]. Both residual circulating and liver MAIT 
cells show signs of activation [149, 179-181], which are higher in the liver than in the blood 
[180], and circulating MAIT cells are dysfunctional to TCR stimulation [180, 181]. 
Successful HCV-clearance therapy does not revert the decline in MAIT cells and their 
dysfunctionality in blood [86, 149, 180-182], but was reported to increase their levels and 
decrease their activation status in the liver [180]. In patients with HCV/HIV co-infections, 
MAIT cells in peripheral blood were detected at even lower levels than in HCV mono-
infection alone [86, 179, 182]. In contrast, chronic hepatitis B virus (HBV) infection appears 
to only exert mild effects on MAIT cells, as recent studies found them not depleted in either 
the blood or in the liver of chronic HBV-infected patients [88, 183]. Moreover, circulating 
MAIT cells seem functionally intact, and their higher activation status when compared with 
healthy controls could be reversed by anti-viral therapy [183].  
1.2.9.5 Cancer, autoimmune diseases, and other clinical conditions 
The first studies examining MAIT cells in cancer reported the detection of the Vα7.2-Jα33 
rearrangement in kidney and brain tumors [184], as well as in peripheral T cell lymphomas 
[185]. Subsequently, infiltration of MAIT cells in tumor tissues and metastases was reported 
in patients suffering from colon or colorectal cancer [186-190]. This indicates the capacity of 
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MAIT cells to infiltrate tumor tissues but further studies are warranted to ascertain their 
precise role in cancer development.  
MAIT cells have also been studied in a variety of autoimmune diseases and other clinical 
conditions, such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, 
systemic lupus erythematosus, asthma, obesity, juvenile type 1 diabetes, adult type 2 diabetes 
[reviewed in detail in 159, 191], and common variable immunodeficiency (CVID) [192]. 
Briefly, levels of circulating MAIT cells are decreased in patients with the aforementioned 
clinical conditions, except for children with type 1 diabetes or obesity, where circulating 
MAIT cell levels are reportedly unchanged or increased, respectively [159, 191, 192]. To 
date, investigation of MAIT cells in multiple sclerosis presents conflicting data [159, 191], 
and future studies are needed to clarify if and how their levels are affected in this disease. 
Lastly, it should be noted that the precise role of MAIT cells in most of the aforementioned 
infections and clinical conditions (protective, pathogenic, or modulatory) remains to be 
determined, as most studies thus far have focused on their changes in frequency and on their 
functionality in peripheral blood and tissues. 
 
1.3 HEPATITIS DELTA 
The discovery of the hepatitis delta virus (HDV) goes back to 1977, when Rizetto et al. [193] 
detected a novel antigen, then named delta antigen, in hepatocytes from HBV-infected 
patients [193]. This antigen was initially considered a new biomarker of HBV infection [194], 
but was later on associated with an HBV-dependent RNA virus [195].  
The HDV virion (35-37 nm in diameter) [195, 196] contains a single-stranded circular RNA 
genome that encodes only one protein, the hepatitis delta antigen (HDAg) [197-200]. HDV 
depends on host proteins for its replication and on HBV for its assembly, during which the 
HDV genome and HDAgs are enveloped by a lipid bilayer containing the HBV surface 
antigens (HBsAg) [195, 201, 202]. Therefore, hepatitis delta occurs in HBV-infected patients, 
and results from either simultaneous HBV-HDV co-infection of a naïve individual, or from 
HDV superinfection of a chronic HBV-infected patient [202, 203]. Similar to HBV, HDV is 
predominantly transmitted parenterally through contact with infected body fluids [202]. 
It is estimated that approximately 20 million people worldwide are infected with HDV [202, 
204]. HBV/HDV co-infections cause the most severe form of viral hepatitis, and these 
patients have a higher risk of developing cirrhosis and hepatocellular carcinoma than HBV 
mono-infected patients [205, 206]. Although there is no established treatment for hepatitis 
delta, different therapeutic strategies based on the administration of pegylated-IFNα and HBV 
polymerase inhibitors are currently employed [202, 204]. HDV is a non-cytopathic virus 
[207], and the pathogenesis of hepatitis delta is believed to be mediated by the immune 
system [202, 204]. Despite this, both the innate and adaptive immune responses against HDV 
are defective. In fact, NK cells are functionally impaired [208, 209] and T cell responses are 
weak [210-213] during HDV infection. 
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2 AIMS 
 
The overall aim of this thesis was to study the immunobiology of human MAIT cells and 
their functions in antimicrobial immunity. MAIT cells were relatively recently discovered, 
and the laboratory tools to specifically study these cells in humans - initially the monoclonal 
antibody against the highly conserved TCR Vα7.2 segment, and more recently the MR1 
tetramers – became available during the last few 2 to 7 years. Given the novelty of these cells 
and tools, we first aimed to establish methodologies to specifically study MAIT cell functions 
in vitro. We then sought to investigate their responses to different stimuli and the possible 
compartmentalization of this cell population. Ultimately, we investigated if, how and why 
MAIT cells are affected in viral hepatitis infections in humans.  
The specific aims of this thesis were to: 
• Optimize and establish methodologies to study the diverse functions of MAIT cells, 
including activation, cytokine production, proliferation, degranulation, as well as their 
ability to kill target cells (paper I). 
 
• Investigate the existence of potential heterogeneity within the MAIT cell population 
with regard to their surface immuno-proteome and their responses to TCR-dependent 
and –independent stimuli (paper II). 
 
• Dissect the phenotypic and functional differences between CD8+ and DN MAIT cells, 
and investigate the relationship between these two cell subsets (paper III). 
 
• Determine the levels, phenotype, and functionality of MAIT cells in patients 
chronically infected with HDV, in comparison with chronic HBV mono-infected 
patients and healthy controls (paper IV).  
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3 METHODOLOGY 
 
In this section, a summary of the main experimental approaches is presented. Paper I and 
paper SIII are method-dedicated articles that describe in detail methodologies optimized and 
established throughout the conduct of this thesis. The methods specifically used in each study 
are described in each paper.  
The assays performed throughout this thesis can be broadly divided into phenotypic and 
functional experiments. 
3.1 PHENOTYPIC EXPERIMENTS 
These experiments aimed at determining the basal expression levels of surface and 
intracellular molecules in MAIT cells and other T cell populations. To this end, peripheral 
blood mononuclear cells (PBMCs) or cell suspensions obtained from tissues were stained 
with specific fluorochrome-labeled antibodies, and the expression levels were then 
determined by flow cytometry. Samples were acquired on an LSRFortessa flow cytometer 
(BD Biosciences) equipped with 355-, 405-, 488-, 561-, and 639-nm lasers, and they were 
analyzed using the FlowJo software version 9.8 or 9.9 (TreeStar). 
3.2 FUNCTIONAL EXPERIMENTS 
3.2.1 Experimental approaches 
Functional experiments were conducted to study the activation, proliferation, and cytotoxicity 
of MAIT cells. They required either PBMC mixtures as the source of MAIT cells and APCs 
(Figure 5A), or magnetically purified Vα7.2+ cells as the MAIT cell source, and autologous 
monocytes or the 293T cell line stably transfected with human MR1 (293T-hMR1 cells) as 
APCs (Figure 5B). In some functional experiments, pure MAIT cell populations obtained by 
fluorescence-activated cell sorting (FACS) were directly cultured with monocytes (Figure 
5C). Microbes, either E. coli or C. albicans, were used as the source of MAIT cell antigens. 
In selected experiments, PBMCs were cultured with the cytokines IL-12 and IL-18 to assess 
MAIT cell activation in response to an innate cytokine stimulus (Figure 5A). The readouts of 
these assays (broadly presented in Table 1) were ultimately determined by flow cytometry 
using the same data acquisition instrument and analysis software as described in Section 3.1.  
3.2.2 Selection of experimental approach 
Specific experimental approaches were selected based on the type of assay to be performed 
and the type of biological material available. PBMC mixtures (Figure 5A) allowed for MAIT 
cell functions to be assessed in the presence of other cell types, and both direct and bystander 
activation of MAIT cells occurred in this system. It was particularly useful when using 
patient samples (paper IV), as the amount of cells was usually limited and further 
purification procedures would have resulted in significant cell loss. 
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Figure 5. Summary illustration of the functional assays performed throughout this thesis. The papers 
where the assays have been used are indicated in brackets. 
 
Table 1. MAIT cell functional readouts. Readouts assessed in MAIT cell analyses at the end of the activation, 
proliferation, and cytotoxicity assays. In some cytotoxicity assays, target cell death was also evaluated 
Assays Surface readouts Intracellular readouts 
Activation 
CD69 
CD25 
CD38 
HLA-DR 
PD-1 
TIM-3 
 
IFNγ 
TNF 
IL-17 
Proliferation  
 
CTV dilution 
 
Cytotoxicity CD107a 
GrzA 
GrzB 
Prf 
Gnly 
 
Magnetic-activated cell sorting (MACS) of Vα7.2+ cells (Figure 5B) (paper I) was suitable 
for obtaining a MAIT cell-enriched cell fraction for detailed studies of MAIT cell activation 
(paper II). In these assays, and due to the fact that Vα7.2+ cells were obtained from 
peripheral blood, monocytes were selected as APCs (Figure 5B). As TCR-mediated 
activation of MAIT cells induces downregulation of the Vα7.2 segment (as well as of CD8), 
this co-culture system where Vα7.2- cells were virtually absent was particularly useful for the 
reliable identification of the MAIT cell population after activation (as discussed in Section 
5.1.4). In this context, MAIT cell identification in stimulated PBMC mixtures (Figure 5A) 
was sometimes challenging, but this system was still deemed the best approach for studying 
patient material with low numbers of cells. Due to the simultaneous downregulation of CD8 
during MAIT cell activation, PBMCs or total Vα7.2+ cells could not be used to investigate 
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the functional differences between CD8+ and DN MAIT cells. Thus, FACS sorting was 
conducted to obtain pure CD8+ and DN MAIT cell populations, and these cells were then 
cultured with autologous monocytes (Figure 5C) (paper III).  
In the cytotoxicity assays aimed at determining the capacity of MAIT cells to kill infected-
target cells, 293T-hMR1 cells, which are relatively resistant to microbe-induced cell death, 
were used as APCs (Figure 5B) (paper I).  
Proliferation assays were established with the Vα7.2+-monocyte co-culture system (Figure 
5B) (paper I) but were also carried out in PBMC mixtures (Figure 5A) when rare MAIT cell 
subpopulations defined by certain TCR Vβ segments needed to be analyzed (paper II).   
3.2.3 Selection of MAIT cell stimulus 
The MAIT cell activating antigens identified to date are intermediate metabolites of the 
riboflavin pathway [51, 52] (described in Section 1.2.6.3). This pathway is present in E. coli 
[52], and this bacterium was used as the natural source of MAIT cell agonists to establish 
methodologies and study MAIT cell functions throughout this thesis (papers I-IV). The 
opportunistic fungus C. albicans, which is also riboflavin biosynthesis-competent [52], was 
used in studies of microbe-dependent functional specialization of MAIT cell responses 
(paper II). The microbes were mildly fixed in formaldehyde before being used in the 
functional experiments to avoid microbial overgrowth during the time of culture. The innate, 
TCR-independent stimulation of MAIT cells was delivered through the combination of IL-12 
and IL-18 (papers II and IV).  
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4 ETHICAL CONSIDERATIONS 
 
All projects in this thesis were performed using human samples from healthy individuals and 
patients. Ethical approval was received from the appropriate Ethics Review Boards to 
conduct the experiments, and written informed consent was obtained from all donors. 
Detailed information about the type of samples and Ethics Review Boards is provided in the 
Materials and Methods section of each paper. However, it is noteworthy that all samples 
were de-identified in the laboratory setting. Additional information about the donors was 
sometimes provided depending on the type of sample and the purpose of the study, but that 
information did not lead to the identification of the donors.  
In papers I to IV, we used peripheral blood from healthy donors, and had the possibility to 
request their gender and year of birth. In paper III, we additionally used endometrial samples 
and fetal spleens. Endometrial samples were accompanied with the donors’ age, as well as 
with other information such as their menstrual status, hormonal treatment, and reason for 
surgery, as previously indicated [65]. For the fetal spleens, we obtained the gestational age 
[75] but no information about the mothers. In paper IV, we used peripheral blood from 
healthy controls, HBV mono-infected and HDV-infected patients, as well as liver biopsies 
from controls and HDV-infected patients. In addition to gender and year of birth, we obtained 
clinical data, including, among others, HBV and HDV viral load (as indicated in paper IV, 
Table 1). As all samples were de-identified, no experimental results were reported back to the 
respective donors. 
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5 RESULTS AND DISCUSSION 
 
5.1 DEVELOPMENT OF METHODOLOGIES FOR MAIT CELL STUDIES 
Adequate methodologies to study immune cell populations and their functions are essential in 
any area of immunology. In a relatively new field of research, such as that of MAIT cell 
studies, new and improved methodologies are crucial to advance knowledge, and their 
characterization and documentation provide the scientific community with basic protocols, 
which can be further adapted according to the questions being investigated. In paper I, we 
described in detail methodologies that we optimized and established to study MAIT cell 
effector functions in vitro, including activation, cytokine production, proliferation, 
cytotoxicity, and ability to kill target cells. These methodologies formed the basis of the 
experimental settings used in papers II and III.  
The established methods rely on a co-culture system of peripheral blood Vα7.2+ cells as the 
source of MAIT cells, and either monocytes (in activation and proliferation assays) or 293T-
hMR1 cells (in cytotoxicity assays) as APCs. In contrast to PBMC mixtures, the composition 
of this system is well defined, which brings several advantages, as discussed in Section 5.1.4. 
In all assays, E. coli was used as the standard activating microbe and natural source of MAIT 
cell agonists.  
Vα7.2+ cells were MACS-sorted by positive selection from healthy individuals’ PBMCs. 
Importantly, positive selection per se did not lead to activation of MAIT cells (paper I, 
Suppl. Fig. 1C), and MAIT cells retained a similar CD4/8 phenotype as that prior to 
purification (paper I, Suppl. Fig. 1B). This analysis was important to ensure that MAIT cells 
in the purified Vα7.2+ cell fraction closely resembled those in the initial PBMC mixture, and 
that subsequent effector functions were not due to purification-driven activation of these 
cells.  
5.1.1 Activation assay 
In order to establish the activation assay, several technical parameters were optimized using 
CD69 upregulation concomitant with IFNγ production (CD69+IFNγ+) as functional readout 
for MAIT cell activation. The parameters optimized included microbial dose (i.e., the E. coli 
colony-forming units (cfu):monocyte ratio), Vα7.2+ cell:monocyte ratio, requirement of anti-
CD28 as a co-stimulatory signal, and duration of the culture (paper I, Fig. 1). Furthermore, 
we tested different E. coli fixation times, and showed that mild fixation of E. coli resulted in 
similar levels of MAIT cell activation as with live E. coli (paper I, Fig. 1B-C). This 
observation justified the use of mild fixation in this type of assay, which is important to avoid 
overgrowth of microbes with short replication times, such as E. coli, during the experiment.  
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The optimized 24 h assay led us to look for other signs of MAIT cell activation. We detected 
upregulation of CD25 (paper I, Fig. 2A), and found that the simultaneous expression of 
CD69 and CD25 is more MR1-dependent than the expression of CD69 alone (paper I, Fig. 
2B-C).  
5.1.2 Proliferation assay 
The proliferation assay was established using dilution of cell trace violet (CTV), a fluorescent 
proliferation-tracing reagent, in MAIT cells as functional readout. We optimized both the 
duration of the culture and the microbial dose, and found the 5-day assay to result in clear 
MAIT cell proliferation patterns that were predominantly MR1-dependent (paper I, Fig. 3). 
The detection of discernible CTV dilution peaks at the end of the assay can be further used to 
selectively study MAIT cells with different proliferation capacities. Of note, peripheral blood 
MAIT cells do not express Ki-67 at resting state [61, 144], and were initially reported to lack 
the capacity to proliferate in vitro [49, 61]. However several reports have since then 
demonstrated their capacity to upregulate Ki-67 following stimulation [144], and their ability 
to proliferate in vitro [57, 75, 144, paper I].  
5.1.3 Cytotoxicity assay 
The cytotoxicity assay was established in order to be able to evaluate the capacity of MAIT 
cells to degranulate and kill target cells. To this end, we used 293T-hMR1 cells as APCs (and 
target cells) because they are relatively resistant to E. coli-induced cell death (paper I, Suppl. 
Fig. 3G). We also pre-treated MAIT cells with IL-7 for 72 h, as this cytokine arms MAIT 
cells into GrzB+Prf+ cytolytic cells (paper SII and paper I, Suppl. Fig. 3A-B). We optimized 
the microbial dose (i.e., the E. coli cfu:293T-hMR1 cell ratio), the effector MAIT cell:target 
293T-hMR1 cell ratio, and the duration of the culture (paper I, Fig. 4).  
Interestingly, this assay allowed us to distinguish between target cell apoptosis - as defined by 
positive staining of 293T-hMR1 cells for the fluorochrome-labeled inhibitor of caspases 
(FLICA; a reagent that labels cells undergoing caspase-mediated cell death), and by negative 
staining for the amine-reactive dead cell marker (DCM) (i.e., FLICA+DCM- cells) - and 
target cell full death defined as FLICA+DCM+. The former occurred within the first 6 h of 
culture, whereas the latter was detected following 24 h co-culture and coincided with MAIT 
cell degranulation, as evaluated by CD107a expression (paper I, Fig. 4E-F). Thus, this assay 
is particularly interesting as it allows the investigation of both the target cells and effector 
cells at the same time.  
5.1.4 Advantages and limitations of the established methodologies 
The assays established in paper I rely on well-defined co-culture systems, with a specific 
source of MAIT cells and MAIT cell agonists, and a defined type of APC. They are, 
therefore, highly versatile and can be adapted to study the effector functions of MAIT cells 
from tissues other than peripheral blood, the effect of APCs other than monocytes, and the 
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stimulatory capacity of microbes other than E. coli. Moreover, different components in the 
system can be blocked in order to investigate their respective involvement in the effector 
functions being studied. This includes not only MR1 and stress ligands in the target cells, but 
also receptors on MAIT cells with a yet unknown function, such as NKG2D.  
When compared with experiments based on PBMC mixtures, the assays we established have 
the advantage of allowing for accurate flow cytometric identification of MAIT cells that have 
been activated or that proliferated in response to E. coli. TCR-mediated MAIT cell activation 
results in downregulation of CD3 and Vα7.2 in a microbial dose-dependent manner (Figure 
6). Thus, accurate identification of MAIT cells by flow cytometry becomes challenging in 
stimulated PBMC mixtures as the MAIT cell population merges with CD3- and Vα7.2- cells 
(Figure 6). This problem is overcome in our system where CD3- and Vα7.2- cells are almost 
absent (Figure 6). On the other hand, proliferating MAIT cells in E. coli-stimulated PBMC 
mixtures downregulate CD161 (paper I, Suppl. Fig. 2A) as previously reported [144], and 
eventually merge with the few CD161-Vα7.2+ cells that have proliferated (paper I, Suppl. 
Fig. 2A). In contrast, we found that CD161 downregulation in our co-culture system is minor, 
with virtually no proliferation of CD161-Vα7.2+ cells (paper I, Suppl. Fig. 2A-B). 
               
Figure 6. Flow cytometric identification of CD3+ cells and MAIT cells. Stimulation of PBMCs (top) or Vα7.2+-
monocyte co-cultures (bottom) for 24 h with varying doses of formaldehyde-fixed E. coli results in strong 
downregulation of CD3 and TCR Vα7.2 on MAIT cells. 
Besides these advantages, isolation of Vα7.2+ cells and monocytes may be challenging when 
the goal is to study MAIT cells from patient samples, as the initial number of cells is already 
low and more purification procedures may lead to extensive cell loss. In these cases, the use 
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of mixed PBMC cultures is more appropriate. Overall, the assays described in paper I offer a 
valuable and versatile platform to study the immunobiology and functions of human MAIT 
cells in different immunologic contexts.  
 
5.2 DIVERSITY OF MAIT CELL ANTIMICROBIAL RESPONSES 
MR1 is highly evolutionarily conserved [41] and, to date, only a limited set of naturally 
occurring MR1-presented MAIT cell agonists, derived from the riboflavin biosynthesis 
pathway, has been identified [51, 52]. These facts have led to the notion that MAIT cells are a 
functionally homogeneous cell population, able to respond to riboflavin biosynthesis-
competent microbes in an undifferentiated manner.  
We investigated this hypothesis by studying the response of total MAIT cells to two highly 
distinct microbes, the bacterium E. coli and the opportunistic fungus C. albicans (paper II). 
When compared with C. albicans, E. coli induced significantly higher levels of IFNγ and 
TNF production by MAIT cells at the optimal microbial dose, as well as stronger 
downregulation of the Vα7.2 segment in a bacterial dose-dependent manner (paper II, Fig. 
1A-D). These results identified E. coli as a potent MAIT cell activating microorganism, 
capable of eliciting a response pattern that may mimic that against potent pathogens. 
Furthermore, analysis of all combinations of IFNγ, TNF, and IL-17 production revealed 
distinct polyfunctional profiles, with MAIT cells responding to E. coli producing more IFNγ 
alone, TNF alone, a combination of IFNγ and TNF, or a combination of the three cytokines, 
compared with C. albicans-responding MAIT cells (paper II, Fig. 1E). Altogether, these 
results demonstrate the existence of microbe-specific MAIT cell response profiles. 
MAIT cells, microbes, and APCs all play a role in MAIT cell responses, and it is reasonable 
to speculate that the functional outcome of microbial encounter by MAIT cells is ultimately 
determined by the interplay between all these components in the system. In Sections 5.2.1 to 
5.2.3, the influence of each component in MAIT cell responses is discussed, and Section 5.2.4 
presents possible implications of the diversity of MAIT cell antimicrobial responses. 
5.2.1 Characteristics of MAIT cells influencing their antimicrobial responses 
5.2.1.1 TCR β chain composition 
In an attempt to further understand factors that influence MAIT cells in their antimicrobial 
responses, we focused on their Vβ segment expression, which, although more restricted than 
that of other T cells [100, 119] (paper II, Fig. 2A and Suppl. Fig. 1-2), still adds some level 
of diversity to the MAIT cell TCR β chain repertoire. Overall, we found that the Vβ segment 
expression influenced MAIT cell responses to E. coli and C. albicans, as Vβ8+, Vβ13.1+, and 
Vβ13.6+ MAIT cells produced less IFNγ and TNF in response to E. coli when compared with 
total MAIT cells (paper II, Fig. 2C-D and Suppl. Fig. 3A). In contrast, only Vβ13.2+ MAIT 
cells responded slightly stronger than total MAIT cells to C. albicans (paper II, Fig. 2C-D 
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and Suppl. Fig. 3B). The fact that the Vβ bias differed between the responses to E. coli and C. 
albicans raises the interesting hypothesis that MR1 may present distinct antigens derived 
from these microbes. 
Previous reports have supported the importance of the CDRα loops in the TCR interaction 
with MR1 [130, 132, 214], and, in particular, the role of the Y95 residue [51, 130, 131] (as 
described in Section 1.2.6.4), which is located in the CDR3α loop and is conserved among the 
Jα33, Jα12, and Jα20 sequences [53] (see Section 1.2.6.2). Overall, it is the TCR α chain that 
predominantly mediates the interaction between the MAIT cell TCR and MR1-ligand 
complexes [132, 214], and this may explain the high conservation of the Vα-Jα 
rearrangements characteristic of MAIT cells [132]. As for the β chain, individual residues 
within the CDRβ loops were reported to be dispensable for MR1 recognition [132]. However, 
several residues within the CDR2β and CDR3β loop were subsequently shown to interact 
with MR1 [130, 214], and it is thus possible that contacts established by the β chain overall 
fine-tune the TCR-MR1-ligand interaction. In this context, and in agreement with our results, 
López-Sagaseta et al. [131, 214] showed that MAIT cell TCRs carrying different Vβ 
segments bound bovine MR1, or humanized bovine MR1 in complex with a MAIT cell 
agonist with different affinities. Another study, however, showed that the interaction affinity 
was determined by the CDR3β loop rather than the Vβ segment itself [125]. Of note, only a 
limited set of TCRs were evaluated in this study, and the functional outcome was assessed 
using TCR-transfected SKW3 cells and C1R.MR1 cells pre-incubated with synthetic ligands 
[125]. In contrast, our assay allowed screening of a much larger number of TCRs in a 
naturally occurring MAIT cell population responding to a natural source of MR1 ligands.  
We also assessed the influence that Vβ segment expression has on the proliferative capacity 
of MAIT cells. Following a five-day culture of CTV-labeled PBMCs in the presence of E. 
coli and IL-2, we found that the initially less abundant Vβ-defined MAIT cell subpopulations 
were less proliferative in vitro (paper II, Fig. 3). In fact, there was an inverse correlation 
between the initial frequency of Vβ-defined MAIT cell subpopulations in the PBMC mixture 
and the CTV geometric MFI in these subpopulations after five days of culture (paper II, Fig. 
3B). These findings raise the possibility that the in vivo interaction of MAIT cells with 
microbes, such as those that compose the microbiota, may overall shape the Vβ repertoire of 
MAIT cells, as cells carrying more responsive TCRs may expand to a greater extent than less 
responsive ones. Our data on the differential responsiveness of Vβ-defined MAIT cell 
subpopulations (paper II, Fig. 2C-D and Suppl. Fig. 3) are consistent with this notion. 
Interestingly, and in light of this hypothesis, one can speculate that the MAIT cell Vβ 
repertoire will differ between individuals with distinct features known to affect the 
microbiota, such as geographic location, diet, and use of medication [215, 216]. In a recent 
study, Hinks et al. [95] reported that the levels of MAIT cells were decreased in the 
peripheral blood and bronchial tissue of steroid-treated patients with chronic obstructive 
pulmonary disease (COPD), in comparison with non-treated patients. Moreover, 
corticosteroids negatively affected MAIT cell antibacterial responsiveness in vitro [95]. 
Whether this or any other of the aforementioned factors contribute to the shaping of the 
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MAIT cell Vβ repertoire through their effect on the microbiota composition is currently 
unknown. This question could potentially be addressed by studying MAIT cells in cohorts of 
individuals that have been previously used in extensive microbiota studies [215, 216].  
In summary, we conclude that the TCR β chain has some influence on the MAIT cell 
recognition of MR1-ligand complexes. Thus, the relative abundance of different Vβ-defined 
MAIT cell subpopulations, which may have already been determined by microbial encounter 
in vivo, may shape the MAIT cell responses to the same microbe as well as distinct microbes. 
5.2.1.2 CD8 co-receptor expression 
Given that CD8+ and DN MAIT cells represent the majority of circulating MAIT cells in 
healthy adults [50, 63], we investigated the responsiveness of these subsets to E. coli 
stimulation in vitro (paper III, Fig. 3). Previous studies have evaluated responses of these 
MAIT cell subsets to H. pylori [97] and PMA/ionomycin [217]. However, because these 
experiments were conducted using PBMC mixtures [97, 217] and the CD8 molecule is partly 
downregulated upon activation (paper III, Suppl. Fig. 2A), it is possible that stimulated DN 
MAIT cells in these experiments represented a mixture of bona fide DN MAIT cells, and 
CD8+ MAIT cells that have downregulated CD8 following activation. In our experiments, we 
first FACS-sorted CD8+ and DN MAIT cells (Figure 5C), and then separately stimulated 
these purified MAIT cell subsets. We found that CD8+ MAIT cells responded more strongly 
to E. coli, with significantly higher production of IFNγ, TNF, and GrzB than DN MAIT cells 
(paper III, Fig. 3). The superior responsiveness of CD8+ MAIT cells was consistent with 
their higher expression levels of CD2 and CD9 (paper III, Fig. 1B-C and Suppl. Table 1), 
both T cell co-stimulatory molecules [218, 219], the cytotoxic molecules GrzB, Prf, and Gnly 
(paper III, Fig. 1B-C), and the transcription factors T-bet and Eomes (paper III, Fig. 2).  
In classical models of T cell activation, TCR engagement induces the recruitment and 
clustering of the TCR/CD3 complexes to specific cell membrane domains with a distinct 
molecular composition known as rafts or detergent insoluble glycolipid-enriched (DIG) 
fractions [220, 221]. The TCR/CD3 complex recruitment is accompanied by accumulation of 
signal-transducing substrates and enzymes in the DIG fractions, and results in early 
downstream TCR signaling cascades, which lead to T cell activation [220, 221]. Yashiro-
Ohtani et al. [222] showed that CD2, CD5, and CD9 are present in the DIG fractions, and 
that they exert their T cell co-stimulatory effects by enhancing the association between the 
TCR/CD3 complexes and these fractions [222]. Although we did not detect any major 
differences in the expression of CD5 between CD8+ and DN MAIT cells (paper III, Suppl. 
Table 1), it is plausible that the higher surface expression of CD2 and CD9 by CD8+ MAIT 
cells may partly explain their stronger responses to TCR stimulation.  
The higher GrzB content in resting CD8+ MAIT cells (paper III, Fig. 1B-C), although low 
when compared with stimulated cells, is consistent with their superior capacity to produce 
GrzB following E. coli stimulation (paper III, Fig. 3). This, combined with higher basal 
levels of Prf could possibly translate into a superior killing capacity of CD8+ MAIT cells 
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when compared with their DN counterparts. In an interesting study where TCR αβ transgenic 
mice were used to compare the functionality of positively selected αβ CD8+ T cells and non-
positively selected αβ DN T cells, Caveno et al. [223] showed that CD8+ T cells were more 
efficient in killing target cells, and they were also superior in antigen-driven proliferation and 
IL-2 production when compared with their negative counterparts (although IFNγ production 
was similar between subsets) [223]. While it is tempting to speculate that a similar cytolytic 
bias for human CD8+ MAIT cells may exist, cytolytic assays, potentially similar to those 
established in paper I, are required to truly compare the killing capacity of CD8+ and DN 
MAIT cells.  
It is currently not known why CD8+ MAIT cells are functionally superior to DN MAIT cells. 
In conventional CD8+ T cells, CD8 binds the α3 domain of the MHC class I molecule, 
thereby increasing the avidity of the CD8+ T cell-APC interaction [224, 225]. In a similar 
manner, it is possible that CD8 stabilizes the interaction between the MAIT cell TCR and the 
MR1-ligand complex, leading to stronger CD8+ MAIT cell responses. Consistent with this 
hypothesis, CD8 blockade was shown to decrease MAIT cell responses to E. coli [226]. 
Interestingly, however, it differently affected MAIT cell functional readouts, with the 
production of IFNγ and TNF decreasing more than degranulation upon CD8 blocking [226]. 
In a similar pattern, Caveno et al. [223] showed that CD8 blockade decreased the 
proliferation capacity of CD8+ T cells to levels similar to that of DN T cells, whereas the 
killing efficiency and IL-2 production were not affected to the same extent [223]. Altogether, 
these studies suggest that while direct CD8 binding to MR1 may influence CD8+ MAIT cell 
effector functions, other cell intrinsic or environmentally driven mechanisms, which remain 
to be determined, may also be involved. Of note, because the use of a CD8 blocking antibody 
may have secondary effects in the assays, such as preventing the interaction between the TCR 
and the antigen-presenting molecule, experiments where either potential CD8 binding sites in 
MR1 are disrupted or the CD8 gene is deleted through the clustered regularly interspaced 
short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas 9) genome editing 
platform would be important to further investigate the effect of CD8 in MAIT cell functions 
[226]. 
Stimulation of CD8+ and DN MAIT cells with PMA/ionomycin showed a similar pattern of 
responses, with CD8+ MAIT cells producing IFNγ and TNF at higher levels than DN MAIT 
cells (paper III, Fig. 3). Interestingly, however, DN MAIT cells produced significantly more 
IL-17, although its levels were much lower than those of IFNγ or TNF (paper III, Fig. 3). A 
recent study on patients with primary Sjögren’s syndrome where MAIT cells are polarized 
towards IL-17 production has shed light on the cellular pathways leading to IL-17 production 
[227]. These involved IL-23 and IL-7, which induced upregulation of RORc, or STAT3 and 
HIF1α transcripts, respectively, ultimately leading to IL-17 production [227]. It is thus 
possible that these pathways are overrepresented in peripheral blood DN MAIT cells.  
IL-17 is a pro-inflammatory cytokine that plays a protective role against infections by several 
species of bacteria and fungi [228, 229]. Interestingly, it is essential in protection against C. 
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albicans, as IL-17R deficient mice were reported to be highly susceptible to this pathogen 
and eventually succumbed to the infection [230]. Whether DN MAIT cells also produce more 
IL-17 than CD8+ MAIT cells in response to C. albicans has not been evaluated. However, 
one can speculate that DN MAIT cells may contribute with IL-17 production to the overall 
MAIT cell antimicrobial response, adding on to Th1 cytokines and cytotoxic molecules 
produced at higher levels by CD8+ MAIT cells. Of note, and similar to other pro-
inflammatory cytokines, excess IL-17 contributes to pathology and tissue damage, and it is 
the balance in the levels of these different pro-inflammatory mediators that determines the 
outcome of the immune response to a specific pathogen (i.e., protective vs. pathogenic) [228, 
229].  
Overall, we can conclude that CD8+ MAIT cells display superior functionality to TCR and 
mitogen stimulations, and the relative abundance of CD8+ MAIT cells may, therefore, also 
shape MAIT cell antimicrobial responses. Importantly, we have not directly assessed the 
responsiveness of purified CD8+ and DN MAIT cells to C. albicans. However, if the higher 
responsiveness of CD8+ MAIT cells is predominantly dictated by CD8 binding to MR1, it is 
likely that we would obtain similar results with C. albicans. Nonetheless, similar activation 
experiments are required to confirm this hypothesis. In addition, it would be interesting to 
evaluate other antimicrobial functions besides activation and cytokine production in order to 
ascertain whether the superior functionality of CD8+ MAIT cells is maintained throughout 
other effector functions.  
CD4+ MAIT cells represent only a minor subset of total MAIT cells, and only approximately 
one third of this subset defined by the expression of Vα7.2 and high levels of CD161 stains 
with the MR1 5-OP-RU tetramer (paper III, Fig. 1A), in agreement with previous reports 
[53, 226]. Kurioka et al. [226] reported marked phenotypic and functional differences 
between CD4+ MAIT cells and the other two subsets [226]. Upon E. coli stimulation, and in 
contrast to CD8+ and DN MAIT cells, CD4+ MAIT cells produced less cytotoxic molecules 
and Th1 cytokines but more Th2 cytokines than CD8+ and DN MAIT cells [226]. However, 
these results should be carefully interpreted as CD4+ MAIT cells were identified in these 
specific experiments based on CD161 and Vα7.2 co-expression [226], and the presence of 
non-MR1 restricted T cells, possibly not responsive to E. coli, may underestimate the overall 
functionality of bona fide CD4+ MAIT cells.  
5.2.1.3 Conclusions on the characteristics of MAIT cells influencing their antimicrobial 
responses 
In summary, we show that MAIT cell TCR-mediated responses may be influenced by two 
factors intrinsic to the MAIT cells themselves: the TCR β chain composition and CD8 
expression. Vβ-defined MAIT cell subpopulations are associated with different degrees of 
responsiveness to microbial stimulation, and CD8+ MAIT cells display higher functional 
capacity than DN MAIT cells both to microbial and mitogen stimulations. 
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These independent observations led us to evaluate the relationship between Vβ segment 
expression and CD8 expression on MAIT cells. While we showed that CD8+ MAIT cells 
were superior in their in vitro responsiveness when compared with DN MAIT cells (paper 
III, Fig. 3), direct comparison of the abundance of Vβ-defined subpopulations with different 
degrees of functionality between CD8+ and DN MAIT cells has not been previously 
performed. Strikingly, this analysis showed that the E. coli-hyporesponsive Vβ13.1+ and 
Vβ13.6+ MAIT cells were significantly more abundant in CD8+ MAIT cells, as were Vβ7.2+ 
MAIT cells for which we found no differences in functional capacity in comparison with total 
MAIT cells (paper II, Fig. 2D and Suppl. Fig. 3) (Figure 7). As Vβ13.1+ and Vβ13.6+ MAIT 
cells cover less than 8% of the total CD8+ MAIT cell population (paper III, Fig. 5C), one 
can speculate that the predominance of other responsive Vβ-defined MAIT cells may 
overcome the lower functional capacity of these two Vβ-defined subpopulations in CD8+ 
MAIT cells. It should also be noted that there are other Vβ-defined MAIT cell subpopulations 
for which we did not assess the in vitro functionality (paper III, Fig. 5C), and these will 
contribute to shape the overall functional capacity of CD8+ and DN MAIT cells.  
 
Figure 7. Frequency of Vβ-defined MAIT cell subpopulations in resting CD8+ and DN MAIT cells. Data are 
from 14 to 16 donors. Lines represent individual donors. The Wilcoxon’s test or paired t test was used to detect 
significant differences between the paired samples. * p < 0.05; ** p < 0.01; *** p < 0.001. 
Given the differences in functionality dictated by both the TCR β chain and CD8 expression 
in peripheral blood MAIT cells, one could expect accumulation of non-hyporesponsive Vβ-
defined subpopulations and highly functional CD8+ MAIT cells at sites where microbial 
encounter is more likely to occur, such as the liver and the gut, to benefit the host. In 
particular, the presence of Vβ13.2+ MAIT cells, which cover a significant proportion of the 
MAIT cell population (paper II, Fig. 2A and paper III, Fig. 5C), could potentially boost 
anti-C. albicans immune responses at sites of colonization, such as the genitourinary and 
oropharyngeal tracts [231]. While the Vβ repertoire has not been analyzed in MAIT cells 
from sites other than the blood, CD8+ MAIT cells from rectal mucosa were shown to express 
higher levels of genes associated with activation and pro-inflammatory functions, including 
TNF, IL-23R, and CD40L, than their negative counterparts [153]. In another study, liver 
CD8+ MAIT cells were the main producers of IFNγ within the MAIT cell population in 
response to TLR8 agonist stimulation of hepatic cells [88]. More studies dissecting the 
composition of tissue MAIT cells in terms of their Vβ segment and CD8 expression would be 
important in this context. 
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Overall, we can conclude that both the TCR β chain composition and CD8 expression affect 
the type and magnitude of peripheral blood MAIT cell effector functions, and contribute to 
the functional heterogeneity they display in their array of antimicrobial responses (Figure 8). 
5.2.2 Influence of microbial characteristics on MAIT cell responses 
5.2.2.1 Production of MAIT cell antigens and other microbial products 
The riboflavin biosynthesis pathway, present in many species of bacteria and fungi [121, 
122], is the only natural source of MAIT cell activating antigens identified so far (see Section 
1.2.6.3). This pathway is present in both E. coli and C. albicans [52], but diverse factors may 
influence their capacity to activate MAIT cells and contribute to the differential responses 
detected (paper II, Fig. 1A-E).  
The type and concentration of MAIT cell agonists and antagonists likely depend on the type 
of microbe and on its growth phase. The most potent agonist identified to date, 5-OP-RU, 
requires 5-A-RU and either glyoxal or methylglyoxal for its formation [51] (see Section 
1.2.6.3). The local concentration of these precursors may, therefore, dictate the amount of 5-
OP-RU generated [107]. The strong Vα7.2 downregulation detected following MAIT cell 
activation with E. coli (paper II, Fig. 1C) suggests that this microbe may produce more 
potent or more abundant MAIT cell agonists. On the other hand, the natural MAIT cell 
antagonists derive from folic acid acquired from the diet [52, 125, 126] (see Section 1.2.6.3), 
and the concentration of folic acid at MAIT cell effector sites might also determine the 
amount of antagonists locally available. Of note, it is clearly possible that other, still-
unidentified MAIT cell antigens exist with other requisites for their formation. Overall, the 
fine balance between the type and concentration of agonists and antagonists will likely 
influence the MAIT cell functional outcome upon microbial encounter, similar to what has 
been shown in in vitro competition experiments between MAIT cell agonists and antagonists 
[125, 126, 129]. 
Interestingly, there is also the possibility that other microbial products interfere with MAIT 
cell responses without binding to MR1. Such an hypothesis was proposed in a recent study 
where lactate added to cultures partially mimicked the effect of Lactobacilli-derived cell free 
supernatant in decreasing the activation of NK and T cells in response to S. aureus [232]. 
These findings suggested an immunomodulatory role for lactate in lymphocyte activation 
[232]. Other studies have demonstrated that short chain fatty acids that are produced during 
bacterial fermentation, including acetate, propionate, and butyrate, promote T cell 
differentiation into Treg cells, as well as into Th1 or Th17 cells depending on the cytokine 
milieu [233, 234]. Thus, it is plausible that, when locally released, these types of compounds 
may affect MAIT cell responses to the microbes producing them as well as to adjacent 
microbes. 
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5.2.2.2 Differential propensity for phagocytosis and PAMP repertoire 
Geometric parameters, such as size and shape, can influence phagocytosis of particles [235]. 
The microbes E. coli and C. albicans are very distinct in size and morphology. E. coli is rod-
shaped [236], whereas C. albicans is a bigger microbe that can grow as unicellular yeast, 
filamentous hyphae, or filamentous pseudohyphae [237]. Thus, one can assume that the 
strikingly different physical properties of E. coli and C. albicans will influence their 
propensity to be phagocytosed, and ultimately their abundance (or intracellular microbial 
load) in the APCs. Salerno-Goncalves et al. [134] showed, using a B cell line as APC and 
Salmonella enterica serovar Typhi and E. coli as microbes, that the quality of the MAIT cell 
response (i.e., the type of cytokines produced) may depend on the bacterial load [134]. This 
raises the interesting hypothesis that MAIT cell responses to E. coli and C. albicans may also 
be shaped by the intracellular concentration of these microbes. 
Given the highly distinct nature of these microbes, the PAMPs expressed on their surface are 
likely to be different and may trigger different TLRs on the APCs. Exposure to different TLR 
agonists in E. coli-stimulated cultures was shown to positively or negatively influence MAIT 
cell IFNγ production [113]. Thus, the PAMP-TLR interactions are likely to represent another 
factor through which MAIT cell antimicrobial responses may be shaped.  
5.2.2.3 Conclusions on the influence of microbial characteristics on MAIT cell responses 
Overall, we can conclude that a wide array of microbe-intrinsic factors may shape MAIT cell 
effector functions, ranging from their physical properties and surface phenotype to the type 
and abundance of MAIT cell antigens and other microbial products (Figure 8). The 
combination and interplay between all these factors is also likely to influence the amount of 
microbe that is necessary for optimal MAIT cell responses. While we have already reported 
that E. coli induced significantly higher levels of IFNγ than C. albicans (paper II, Fig. 1A-B, 
D), it is noteworthy here that the optimal dose of E. coli required to reach maximal MAIT cell 
activation, as assessed by the upregulation of CD69 and production of IFNγ, was much 
higher than that of C. albicans (paper II, Fig. 1B).  
5.2.3 Influence of APC characteristics on MAIT cell antimicrobial responses 
5.2.3.1 Repertoire of co-signaling receptors 
The MAIT cell effector functions against E. coli and C. albicans (paper II, Fig. 1-2) were 
studied using monocytes as APCs (paper I, Fig. 1). In our experimental system, we found 
that the addition of anti-CD28 in the monocyte-Vα7.2+ cell co-cultures stimulated with E. 
coli boosted MAIT cell IFNγ production (paper I, Fig. 1E). This indicates that monocytes 
are not intrinsically very efficient in delivering co-stimulatory signals, and, importantly, that 
the magnitude of the MAIT cell response depends to some degree on the level of co-
stimulation provided by the APC. Moreover, E. coli stimulation of MAIT cells induced only 
modest upregulation of the co-inhibitory receptor T-cell immunoglobulin and mucin domain-
containing protein-3 (TIM-3) (paper I, Fig. 2A). Overall, and in a similar manner to 
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conventional T cells [238], it is likely that the repertoire of co-stimulatory and co-inhibitory 
receptors expressed by the APC will influence both the type and magnitude of MAIT cell 
responses.  
5.2.3.2 MR1 antigen presentation 
MR1 is mostly kept intracellularly at resting state and it traffics to the cell surface in a process 
dependent on APC activation (see Section 1.2.6.1). In our activation experiments, MR1 
blocking led to discrepant results with regard to the production of IFNγ and TNF. IFNγ 
production was mostly MR1-dependent, but a certain amount of this cytokine was still 
produced independently of the TCR-MR1 interaction (paper II, Fig. 1F-G). In contrast, the 
MR1-dependency of TNF production was significantly higher than that of IFNγ, and almost 
no TNF was detected upon MR1 blocking (paper II, Fig. 1F-G). These results suggest the 
existence of variable requirements for production of different cytokines in MAIT cells. The 
dependency on TCR-MR1 interaction for the production of virtually all of the TNF and most 
of IFNγ shows that MAIT cell pro-inflammatory responses are tightly regulated. This may be 
particularly important in order to avoid such responses against riboflavin biosynthesis-
competent microbes from the microbiota, which may be in close proximity to MAIT cells but 
not actively producing MAIT cell agonists at steady state. Of note, the fact that MR1 is not 
constitutively expressed on the APC surface at steady state may also be considered a MAIT 
cell activation regulatory mechanism. As it was shown that MR1 can bind extracellular 
ligands directly on the cell surface [114] (see Section 1.2.6.1), the existence of potential MR1 
ligands from commensal microbes, even if at homeostatic levels, could otherwise result in 
unnecessary MAIT cell pro-inflammatory responses.  
5.2.3.3 Production of innate cytokines 
As microbes activate APCs not only to upregulate co-stimulatory molecules but also to 
secrete cytokines, such as IL-12 and IL-18 [1], the MR1-independent MAIT cell IFNγ 
production may be due to the direct stimulatory effect of monocyte-derived cytokines on 
MAIT cells. Given that MAIT cells express IL-12R and IL-18R [49, 70, 71], it is plausible to 
assume that these cytokines contribute to MR1-independent activation of these cells upon 
microbial encounter. In paper II (Fig. 5D-E), we showed that CD56+, CD84+, and CD94+ 
MAIT cells display a higher capacity to respond to innate cytokines than their negative 
counterparts. Thus, the relative proportion of these MAIT cell subsets might influence the 
overall MAIT cell antimicrobial responses. As MAIT cell responses against viruses are 
probably primarily driven by innate cytokines (see Section 1.2.7.5), these findings are 
discussed in more detail in Section 5.4.1, in the context of MAIT cell involvement in viral 
hepatitis. 
5.2.3.4 Conclusions on the influence of APC characteristics on MAIT cell antimicrobial 
responses 
In conclusion, several aspects of APCs may shape MAIT cell antimicrobial responses, 
including the repertoire of co-stimulatory and co-inhibitory receptors, the surface expression 
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of MR1-antigen complexes, and the innate cytokines they produce upon microbial exposure 
(Figure 8).  
Given the ubiquitous expression of MR1 [40, 47, 110], many cell types apart from monocytes 
can present antigens to MAIT cells (see second paragraph of Section 1.2.7.3). Professional 
APCs, namely DCs, macrophages, and B cells, are capable of microbe internalization and 
intracellular processing, as well as of delivering co-stimulatory signals to T cells [1]. In 
addition, APCs produce different types of innate cytokines upon stimulation [239], and the 
occurrence and extent of MR1 upregulation varies among cell types [113]. As all of these 
factors vary with the type of APC, they will likely also influence the type and magnitude of 
MAIT cell responses. In antimicrobial responses in vivo, where MAIT cells are more likely to 
respond to a mixture of different microbe-exposed APCs, the panel of MAIT cell responses 
may be ultimately influenced by the type and relative abundance of each APC in the system.  
                     
Figure 8. Summary illustration of the characteristics of MAIT cells, microbes, and APCs that may 
influence MAIT cell antimicrobial responses. 
5.2.4 Implications of the diversity of MAIT cell antimicrobial responses 
Overall, MAIT cell responses to distinct microbes are diverse, and we identified several 
factors influencing the quality and magnitude of the responses. These include the microbial 
dose, the TCR interaction with MR1, as well as the TCR β chain composition and the 
expression of CD8 and NK cell-associated receptors on MAIT cells. The concept of 
functional heterogeneity/compartmentalization has also been shown for conventional CD4+ 
and CD8+ T cells [98, 240, 241]. Strategic location of these different T cell populations at 
sites of microbial encounter combined with their capacity to recognize different types of 
antigens is likely to benefit the host, as these cells help form multifaceted immune barriers for 
immunosurveillance and defense against microbial invaders.  
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MAIT cells represent a significant fraction of the T cell compartment in peripheral blood and 
in the gut, and even more so in the liver (see Section 1.2.5). Factors underlying their 
functional heterogeneity and the immunobiology behind their potent effector responses, 
which we are just now beginning to understand, may be harnessed in the future in the 
development of immunotherapeutic approaches for the treatment of a wide variety of 
diseases. Current immunotherapies include infusion of lymphocytes as well as administration 
of cytokines to augment or dampen pro-inflammatory responses [242-245]. The development 
of MAIT cell-directed therapies should benefit from the knowledge generated in this field 
and, if proven successful, these therapies could potentially be combined with existing 
strategies to ultimately improve treatments and disease outcomes. 
 
5.3 RELATIONSHIP BETWEEN CD8+ AND DN MAIT CELLS 
Although there has been much attention focused on the biology of MAIT cells and their role 
in the immune system, the relationships between MAIT cell subsets has been largely 
unexplored. As CD8+ and DN MAIT cells represent the vast majority of MAIT cells, 
unraveling the relationship between these two cell subsets will be important for our 
understanding of MAIT cell immunobiology. 
5.3.1 Potential transition from CD8+ MAIT cells to DN MAIT cells 
Our analysis of the Vβ segments of adult peripheral blood CD8+ and DN MAIT cells 
revealed that CD8+ MAIT cells expressed a significantly more diverse Vβ repertoire than 
their DN counterparts (paper III, Fig. 5C-D). Strikingly, the Vβ segments detected in DN 
MAIT cells were also present in CD8+ MAIT cells, but not vice-versa. This was initially 
observed when all donors were analyzed collectively (paper III, Fig. 5C). However, the 
same pattern occurred in each individual donor (paper III, Suppl. Fig. 3B), which supports 
the idea that, in any given individual, the Vβ repertoire of DN MAIT cells in vivo is a subset 
of that of CD8+ MAIT cells. This finding, together with the fact that CD8 is downregulated 
from the surface following MAIT cell activation (paper III, Suppl. Fig. 2A), suggests that 
DN MAIT cells may represent a subset of MAIT cells that were originally CD8+ but have 
downregulated the CD8 co-receptor upon activation in vivo.  
This hypothesis is consistent with our data on second-trimester fetal CD8+ and DN MAIT 
cells (paper III, Fig. 5A-B), which we obtained by directed analysis of CD8+ vs. DN MAIT 
cells in human fetal tissues [75]. This analysis revealed that fetal DN MAIT cells were more 
mature than CD8+ MAIT cells, as the former expressed significantly higher levels of 
CD45RO and IL-18R, and lower levels of CD62L and CCR7 (paper III, Fig. 5B). Moreover, 
during gestational development, the frequency of DN MAIT cells in the CD4- MAIT cell 
compartment increased over time, with a corresponding contraction of the CD8+ MAIT cell 
population (paper III, Fig. 5A). This suggests an accumulation of DN MAIT cells during 
fetal development. In agreement with this, Koay et al. [63] recently reported that DN MAIT 
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cells are rare in the thymus but more abundant in young peripheral blood and even more so in 
adult peripheral blood [63]. Collectively, our data on fetal MAIT cells and on the Vβ 
repertoire of adult peripheral blood MAIT cells suggest that DN MAIT cells may derive from 
the larger CD8+ MAIT cell population in vivo.  
In the original study on fetal MAIT cells [75], the combined evaluation of the expression of 
PLZF, CD62L, and CD45RO showed that fetal CD8αα MAIT cells were more mature than 
CD8αβlo MAIT cells, whereas CD8αβhi MAIT cells were essentially naïve [75]. This led to 
the hypothesis that fetal CD8αα MAIT cells could be derived in vivo from CD8αβ MAIT 
cells in a stepwise CD8αβhi à CD8αβlo à CD8αα manner [75]. A similar pattern was 
suggested by Walker et al. [62] for adult peripheral blood CD161hiCD8+ T cells, as 
CD161hiCD8αα T cells could be derived in vitro from CD161hiCD8αβ T cells [62], similar to 
what occurs with conventional CD8+ T cells [246]. Consistent with these findings, CD8+ 
MAIT cells in the thymus and cord blood are exclusively CD8αβ [62, 63] (see Section 1.2.4), 
whereas those in peripheral blood express CD8αα at gradually increasing levels from young 
to adult peripheral blood [63].   
In summary, our data, together with previous findings, suggest that DN MAIT cells may 
derive from CD8+ MAIT cells in the following stepwise model: CD8αβ MAIT à CD8αα 
MAIT à DN MAIT cells.  
5.3.2 Potential transition from DN MAIT cells to cell death 
Further analysis of the MAIT cell subsets revealed that DN MAIT cells were more prone to 
apoptosis than CD8+ MAIT cells both at resting state and following E. coli or 
PMA/ionomycin stimulations (paper III, Fig. 4A-B), as assessed by their higher staining for 
FLICA (paper III, Fig. 4A-B). These results are consistent with the higher expression levels 
of PLZF in adult and fetal DN MAIT cells (paper III, Fig. 2 and Fig. 5B, respectively), 
which was previously shown to drive the pro-apoptotic features of MAIT and iNKT cells 
[247]. In agreement with these findings, Kurioka et al. [226] have recently reported higher 
levels of Annexin V in DN MAIT cells following E. coli stimulation [226]. Of note, the 
higher propensity of DN MAIT cells for apoptosis occurred despite similar expression levels 
of the anti-apoptotic protein Bcl-2 [1, 248] between CD8+ and DN MAIT cells (paper III, 
Fig. 4D). It would be important, nonetheless, to investigate the expression levels of other anti-
apoptotic proteins, such as Bcl-XL, as well as of pro-apoptotic proteins, such as the Bcl-2 
associated X, apoptosis regulator (Bax) and the Bcl-2 antagonist/killer (Bak), as it is the 
overall balance between these proteins that helps dictate the fate of a cell [1, 248]. Moreover, 
it would be interesting to evaluate the expression levels of the X-linked inhibitor of apoptosis 
(XIAP), which was shown to counteract the pro-apoptotic phenotype induced by PLZF on 
MAIT and iNKT cells [247]. 
Given the higher propensity of DN MAIT cells for apoptosis, and in light of the results 
presented in Section 5.3.1, we suggest an irreversible transition from CD8+ MAIT cells to DN 
MAIT cells to eventual cell death. This hypothesis could potentially explain the lower 
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functionality of DN MAIT cells when compared with CD8+ MAIT cells (paper III, Fig. 3) 
(discussed in Sections 5.2.1.2 and 5.2.1.3), as these cells are progressing to cellular 
senescence and eventually cell death. Interestingly, in the aforementioned murine study on 
positively selected αβ CD8+ T cells and non-positively selected αβ DN T cells [223], Caveno 
et al. reported that DN T cells isolated from antigen-exposed mice were functionally anergic, 
as suggested by their poor proliferation and low IL-2 production following antigen 
stimulation in vitro (even though no comparison was made with CD8+ T cells) [223]. 
5.3.3 Conclusions on the relationship between CD8+ and DN MAIT cells 
Altogether, we suggest the following model summarizing the derivative relationships 
between MAIT cell subsets: CD8αβ MAIT à CD8αα MAIT à DN MAIT à cellular 
senescence à cell death. In agreement with this, while CD8+ MAIT cells were detected at 
lower levels in the peripheral blood of chronic HCV-infected patients when compared with 
healthy controls, the levels of DN MAIT cells remained relatively unchanged [180]. This is 
consistent with a model whereby CD8+ MAIT cells downregulate CD8 due to continuous 
engagement and activation during infection. Similar rates of CD8 downregulation and DN 
MAIT cell death may lead to an overall contraction of the CD8+ MAIT cell subset while the 
DN MAIT cell compartment remains stable. The suggested irreversible CD8+ to DN MAIT 
cell transition also implies that in tissues where microbial encounter is common, such as the 
gut, an overall contraction of CD8+ MAIT cells with time as a result of continuous 
engagement of resident or recruited CD8+ MAIT cells could be expected. In this context, it 
would be interesting to investigate the dynamics of these MAIT cell subsets in such tissues 
during homeostasis and upon infection. 
Although our own findings and those of others may support the aforementioned derivative 
model, direct experimental evidence of the relationships suggested are warranted, namely the 
irreversible transitions from CD8+ to DN MAIT cells, and from DN MAIT cell to cell death. 
Long-term stimulation of purified CD8+ and DN MAIT cell populations and evaluation of 
CD8 expression over time would be necessary. Assessment of CD8 intracellular expression 
in ex vivo resting DN MAIT cells at the transcript and protein level would be important for a 
better understanding of the true identity of DN MAIT cells. Are they not equipped at all to 
express CD8, or as we suggest, is CD8 re-expression somehow restricted by yet-unknown 
mechanisms after downregulation? Apoptosis blocking experiments following stimulation 
could help clarify the transition from DN MAIT cells to cell death. If our hypothesis holds 
true, one could in such experiments expect accumulation of DN MAIT cells, while the CD8+ 
MAIT cell population would contract over time. 
 
5.4 MAIT CELLS IN HEPATITIS DELTA 
MAIT cells have been studied in a wide variety of diseases, including cancer, autoimmune 
diseases, as well as bacterial and viral infections. Among the latter, viral hepatitis has 
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received particular attention in recent years, and several reports have been published on the 
involvement of MAIT cells in chronic hepatitis B and C (see Section 1.2.9.4). Hepatitis delta, 
caused by HDV, is the most severe form of viral hepatitis (see Section 1.3). In Paper IV, we 
used precious samples from chronic HDV-infected patients to examine the levels of 
peripheral blood MAIT cells and their functionality in response to TCR and innate cytokine 
stimulations. Chronic HBV mono-infected patients and healthy controls were included as 
comparison groups. Furthermore, we examined liver biopsies taken from HDV-infected 
patients for the presence of MAIT cells, and compared the results with control biopsies.  
We initially found that the levels of MAIT cells were significantly lower in HDV-infected 
patients than in HBV mono-infected patients and healthy controls (paper IV, Fig. 1A-B). In 
contrast, we only detected a mild decrease in MAIT cell levels in HBV mono-infected 
patients when compared with healthy controls (paper IV, Fig. 1A-B). Conventional flow 
cytometry analysis of the dataset revealed that residual MAIT cells in HDV-infected patients 
displayed an abnormal phenotype of activation and exhaustion (paper IV, Fig. 2A-F and 
Suppl. Fig. 1B). In comparison with healthy controls or HBV mono-infected patients, a 
cluster of MAIT cells in HDV-infected patients simultaneously expressing higher levels of 
CD38 and programmed death-1 receptor (PD-1), and lower levels of CD28, CD127, PLZF, 
Eomes, and Helios (CD38hiPD-1hiCD28loCD127loPLZFloEomesloHelioslo cells) was detected 
by high-dimensional Barnes-Hut stochastic neighbor embedding (SNE) analysis (paper IV, 
Fig. 2G-H, J and Suppl. Fig. 1D, F). In contrast, differences in the phenotype of MAIT cells 
from HBV mono-infected patients when compared with healthy controls were only minor 
(paper IV, Fig. 2A-F, I and Suppl. Fig. 1B, E). 
The mechanism(s) that drive MAIT cell loss in chronic HDV infection (or in any other viral 
infection where the levels of peripheral blood MAIT cells were reportedly decreased (see 
Section 1.2.9.4)) are currently unknown. However, several hypotheses have been suggested 
and they are discussed in Sections 5.4.1 to 5.4.4 according to results obtained in this study 
and in previous studies.  
5.4.1 Innate cytokine-mediated activation-induced MAIT cell death 
Plasma cytokine measurements revealed that IL-12 and IL-18 were significantly more 
abundant in the plasma of HDV-infected patients than in healthy controls (paper IV, Fig. 
4A). HDV contains a single-stranded RNA genome rich in guanine and cytosine [199, 200]. 
Thus, it is possible that this virus is recognized by TLR7- and TLR8- expressing cells, which 
in turn may produce IL-12 and IL-18 in response to viral infection, in a similar manner to 
what has been reported for liver monocytes upon TLR8 engagement [88]. MAIT cells may, 
therefore, indirectly respond to HDV through TCR-independent stimulation mediated by IL-
12 and IL-18. In this context, we evaluated the in vitro responsiveness of residual peripheral 
blood MAIT cells from HDV-infected patients to the IL-12 and IL-18 cytokine combination. 
MAIT cells from these patients responded to a similar extent as MAIT cells from HBV 
mono-infected patients and healthy controls (paper IV, Fig. 3A-D). Given that even residual 
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exhausted MAIT cells responded well to innate cytokines, one can speculate that there are 
similarly uncompromised responses during the initial phases of infection before MAIT cells 
are depleted from peripheral blood. At such an early phase of infection, the MAIT cell 
response to innate cytokines may importantly contribute to the overall protective immune 
response against HDV.  
Upon characterization of the surface immunoproteome of MAIT cells from healthy donors, 
we found that these cells were clearly distinct from other T cell populations (paper II, Fig. 
4A-C and Suppl. Table 1). At the same time, they were highly homogeneous in their surface 
immune repertoire, as most of the proteins were either expressed by virtually all MAIT cells 
or none (paper II, Fig. 5A and Suppl. Table 1). Strikingly, however, MAIT cells displayed 
marked heterogeneity in the expression of certain NK cell-associated markers that were 
expressed at intermediate levels (paper II, Fig. 5A-C and Suppl. Table 1). Among them, we 
found that MAIT cells expressing CD56, CD84, and CD94 produced higher levels of IFNγ in 
response to IL-12 and IL-18 than their negative counterparts (paper II, Fig. 5D-E). The 
higher responsiveness of CD56+ MAIT cells was associated with higher basal expression 
levels of Prf, IL-12R, and IL-18R, as well as of PLZF, Eomes, and T-bet (paper II, Fig. 6). 
Thus, through their higher capacity to respond to IL-12 and IL-18, CD56+ MAIT cells may 
be particularly advantageous in the immune response against HDV. Strategic location of this 
MAIT cell subset at sites of inflammation, including the liver, and their relative proportion in 
relation to CD56- MAIT cells may help dictate the overall extent of host immune protection 
against HDV. The proportion of MAIT cells expressing CD56 was reported to be 
significantly higher in the liver than in the peripheral blood of healthy individuals [88, 89, 
226]. It would thus be interesting to determine whether this is maintained throughout the 
course of HDV infection, and if, how and why the viral infection might compromise this cell 
subset over time. 
Despite the intact responsiveness of residual MAIT cells to IL-12 and IL-18 stimulation, we 
also showed that long-term culture in the presence of these cytokines significantly increased 
MAIT cell death in vitro (paper IV, Fig. 4B-C). It is thus possible that continuous activation 
of MAIT cells by these cytokines combined with limited feedback inhibition mechanisms 
leaves these cells vulnerable to persistent activation, ultimately leading to their exhaustion 
and decline in circulation. In agreement with this hypothesis, an IL-18-driven mechanism has 
been suggested to similarly affect iNKT cells in the context of chronic inflammatory disease 
[249]. 
5.4.2 Microbe-mediated activation-induced MAIT cell death 
5.4.2.1 MAIT cell loss by engagement in antimicrobial responses 
It has been hypothesized that the loss of MAIT cells from peripheral blood of HIV-1-infected 
patients is due to continuous engagement of these cells in antimicrobial responses as a 
consequence of microbial translocation [92, 93, paper SI]. In fact, in vitro exposure to E. coli 
has been shown to induce MAIT cell apoptosis and selective loss of this cell population from 
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in vitro cultures in an MR1-dependent manner [92]. Microbial translocation has also been 
shown to occur in chronic HBV and HCV infections [250], and it is possible that this 
phenomenon also occurs during HDV infection. In this context, we studied the in vitro 
response of MAIT cells to E. coli, and found that MAIT cells from HDV-infected patients 
concomitantly failed to upregulate CD69 and CD25, to degranulate as assessed by CD107a 
expression, and to produce GrzB (paper IV, Fig. 3E, F, H and Suppl. Fig. 2C, E). 
Conventional flow cytometry analysis also revealed that MAIT cells from HDV-infected 
patients produced lower levels of IFNγ (paper IV, Fig. 3C-D). Overall, MAIT cell responses 
to TCR stimulation were impaired in HDV-infected patients, whereas MAIT cells from HBV 
mono-infected patients were as functional as those from healthy controls (paper IV, Fig. 3 
and Suppl. Fig. 2C-E). The defective functionality of MAIT cells in hepatitis delta may 
compromise the ability of the host immune system to cope with microbial pathogens, and 
overall contribute to the higher severity of the disease when compared with chronic HBV 
infection alone.  
In conclusion, in HDV infection, continuous engagement of MAIT cells in antimicrobial 
responses is likely to lead to their activation, exhaustion, and consequent loss from peripheral 
blood. Strikingly, the loss of MAIT cells specifically occurred in the CD8+ MAIT cell 
compartment (paper IV, Fig. 1C and Suppl. Fig. 1A), and this finding is in agreement with 
its previously reported superior functionality to TCR stimulation (paper III, Fig. 3) 
(discussed in Sections 5.2.1.2 and 5.2.1.3). Of note, engagement and exhaustion of MAIT 
cells in antimicrobial responses in hepatitis delta may not only be due to TCR stimulation but 
also to the TCR/MR1-independent responses elicited by innate cytokines that derive from 
HDV-infected APCs. 
5.4.2.2 MAIT cell loss by CD161 downregulation following microbial stimulation 
TCR-mediated activation of MAIT cells may lead to strong downregulation of the TCR 
Vα7.2 segment (paper II, Fig. 1C) as well as of the CD8 co-receptor (paper III, Suppl. Fig. 
2A). Similarly, downregulation of CD161 can also occur [93], and it has been hypothesized 
that in HIV-1 infection, the reported loss of MAIT cells from peripheral blood may be partly 
due to the downregulation of CD161 after activation [93]. This would consequently lead to 
underestimation of the frequency of MAIT cells as they become hard to distinguish from 
bona fide CD161- T cells. This hypothesis is so far controversial in the HIV/MAIT cell field. 
While several studies have reported an increase in the levels of CD161-Vα7.2+ cells during 
HIV-1 infection [86, 93, 172, 173, 251], and the proportion of these cells increased in vitro 
following MAIT cell exposure to E. coli [93], one study showed that the expanded CD161-
Vα7.2+ cell population in HIV-1-infected patients did not stain with the MR1 5-OP-RU 
tetramer, therefore claiming that this population does not contain bona fide MAIT cells [173]. 
In HCV infection, the levels of CD161-Vα7.2+ cells in peripheral blood and liver were similar 
to those of healthy controls [86, 181]. In our study, we also did not detect an increase in the 
levels of CD161-Vα7.2+ cells in HDV-infected (or chronic HBV mono-infected) patients 
when compared with healthy controls (paper IV, Fig. 1A-B). Thus, it is unlikely that CD161 
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downregulation in MAIT cells underlies the loss of this cell population from peripheral blood 
in HDV-infected patients.  
5.4.3 MAIT cell recruitment to the inflamed liver 
As peripheral blood MAIT cells express CCR6 and CXCR6 [61] (see Section 1.2.5), one may 
speculate that the decline in circulating MAIT cells in HDV-infected patients may be due to 
their recruitment to the inflamed liver. Immunohistochemical analysis of liver biopsies from 
HDV-infected patients did not show signs of MAIT cell accumulation in the liver (paper IV, 
Fig. 1E), similar to previous reports on liver MAIT cells from chronic HBV-infected patients 
[88]. However, it is still possible that MAIT cells are recruited there and undergo apoptosis 
following engagement in antimicrobial responses, resulting in a lack of net MAIT cell 
accumulation or even a decline in the total MAIT cell pool in that organ over time. Consistent 
with this hypothesis, we detected a significant inverse correlation between the levels of 
peripheral blood MAIT cells and liver fibrosis score in hepatitis patients (paper IV, Fig. 1D). 
Moreover, in patients with chronic HCV infection [86, 180], or HBV or HVC-infected 
patients with end-stage liver disease [88], the levels of liver MAIT cells were significantly 
lower than in healthy controls [86, 88, 180]. Detailed investigation into the MAIT cells in the 
liver at several time points during the course of HDV infection in parallel with the analysis of 
clinical parameters indicative of liver inflammation would be required to better understand 
the numerical and functional dynamics of the hepatic MAIT cell population, and how it may 
be locally affected by this type of viral infection.  
5.4.4 Conclusions on the involvement of MAIT cells in hepatitis delta 
In summary, we found that the MAIT cell compartment is profoundly affected in hepatitis 
delta. We detected a severe decline in the levels of circulating MAIT cells in HDV-infected 
patients that was associated with disease severity, as assessed by the level of hepatic fibrosis. 
Residual circulating MAIT cells showed signs of activation and exhaustion, and were 
functionally impaired in response to TCR stimulation. 
HBV infection alone did not significantly affect the levels or functionality of MAIT cells, a 
pattern consistent with a recent report [183] and with the notion that hepatitis delta presents 
with a more severe clinical scenario than hepatitis B alone [205, 206] (see Section 1.3). This 
also suggests that it is either HDV itself or the clinical consequences of the HBV/HDV co-
infection that profoundly affect MAIT cells during hepatitis delta. Although separate 
hypotheses for the loss of circulating MAIT cells were presented here, it is likely that MAIT 
cell loss results from a dynamic combination of different mechanisms occurring in peripheral 
blood and in the liver. In this context, it would also be interesting to perform multivariate 
analysis of our dataset in order to potentially identify factors independently associated with 
MAIT cell loss from peripheral blood. Although MAIT cells were shown to not be prone to 
direct infection by HIV-1 [92], it would be interesting to evaluate whether HBV and HDV 
can directly infect MAIT cells. Due to their role in antimicrobial responses, it is reasonable to 
speculate that the severe loss of MAIT cells from peripheral blood might compromise their 
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ability to mount robust immune responses. This may contribute to increased sensitivity to 
bacterial infections in patients with severe liver disease.  
MAIT cells represent a dominant fraction of the T cell compartment in the liver, and it is 
reasonable to believe that they constitute an important component for immunosurveillance 
and antimicrobial defense in this organ [159]. In support of this notion, liver MAIT cells are 
more activated than their blood counterparts, as assessed by their higher expression levels of 
CD69, CD38, and HLA-DR [89], and, together with CD56bright NK cells, they are the main 
producers of IFNγ following TLR8 stimulation of liver mononuclear cells [88]. However, due 
to the same fact that liver MAIT cells are highly activated and able to rapidly secrete pro-
inflammatory cytokines, one may wonder about their contribution to the pathogenesis of the 
disease. Mechanistic studies, clinical correlation analyses, and in vivo models may help 
understand the role of MAIT cells in hepatitis delta [159]. Both the innate and adaptive 
immune systems are weakened during chronic HDV infection (see Section 1.3), and 
understanding their respective roles as well as those of the innate-like T cell populations, such 
as MAIT cells, in the protection or pathogenesis of hepatitis delta may help devise efficient 
therapeutic strategies.  
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6 CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
When the work that constitutes this thesis started, research on human MAIT cells had just 
begun, their antigens had not yet been identified, and there were no published studies on their 
involvement in viral diseases. In a relatively short period of time, extensive research in the 
field has greatly advanced our knowledge of the immunobiology of MAIT cells and their role 
in the immune system.  
Specifically in this thesis, we established MAIT cell-based experimental platforms that can be 
used to study several functions of these cells and adapted to answer a wide variety of research 
questions. We showed that MAIT cell responses to distinct riboflavin biosynthesis-competent 
microbes depend on the microbial dose and differ in the type and amount of cytokines 
produced. We demonstrated functional compartmentalization of the MAIT cell population, as 
the TCR β chain composition and CD8 expression, as well as the expression of NK cell-
associated receptors, influence their capacity to respond to TCR and innate cytokine 
stimulation, respectively. In an attempt to understand the relationship between CD8+ and DN 
MAIT cells, we showed that CD8+ MAIT cells are functionally superior to DN MAIT cells 
and that the latter may derive from the former in vivo. Finally, we studied MAIT cells in 
hepatitis delta and showed that they are severely depleted from the peripheral blood of HDV-
infected patients, with the residual MAIT cells being activated, exhausted, and functionally 
impaired in response to TCR stimulation.  
Although specific future experiments have been suggested throughout the discussion of the 
results of this thesis (Section 5), the panel of questions about MAIT cells that remains to be 
clarified is immense. We have come to know a lot about MAIT cell effector functions, but 
much remains to be understood about how they are regulated and modulated in vitro and in 
vivo. Strikingly, the precise function of CD161 has been scarcely studied in the MAIT cell 
field, and the few experiments aimed at investigating its modulatory role have led to 
controversial results. Furthermore, what role does NKG2D have on MAIT cells? Its 
expression was detected in peripheral blood MAIT cells, but whether it is also expressed in 
tissue MAIT cells remains to be determined, as does the effect thereof. On the other hand, the 
production of pro-inflammatory mediators, such as IL-17, appears to be tightly regulated, and 
investigations into how this regulation is achieved and which factors are involved are of 
utmost importance, especially if these cells are to be used in immunotherapeutic approaches 
in the future. 
The involvement of MAIT cells in several diseases is clear. It is particularly striking that 
MAIT cells are depleted from the circulation in most of the diseases where they have been 
investigated, but their recruitment to affected tissues was not always assessed, and even when 
so, not always observed. Whether their sometimes-reported dysfunctionality is a consequence 
or a cause of the disease has not been determined, and, therefore, their exact role as 
protective, pathogenic, or modulatory also remains elusive. It is challenging to investigate 
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these types of questions in humans, but the use of animal models and the study of 
sophisticated cohorts of patients may, in the future, shed light on these questions. 
Given the abundance of MAIT cells at sites of microbial encounter such as the gut, one can 
speculate that failure in their capacity to discriminate between commensal and pathogenic 
microbes would have drastic consequences to the human body. Thus, full understanding of 
the mechanisms and factors that allow such discrimination is required, and will greatly 
advance our knowledge of MAIT cell immunobiology. One may also wonder how the 
microbiota influences this cell population postnatally. Strikingly, could the microbiota be 
involved in shaping the abundance of MAIT cells, and therefore contribute to the high inter-
donor variability in circulating MAIT cell levels? The finding that CD1d-deficient mice have 
more MAIT cells suggests that competition with other innate T cell populations for the same 
niche may occur [63]. If that is the case, the complexity of this question goes beyond MAIT 
cells alone to include the investigation of factors affecting the abundance of other T cell 
populations as well.  
The co-existence of T cells able to recognize antigens of different nature - peptides, lipids, 
and vitamin metabolites - arms the human body with a highly specialized system that can 
perform immunosurveillance at many different fronts and defend against a wide array of 
pathogens. MAIT cells occupy a distinct niche within the global T cell compartment: they are 
abundant in several tissues and recognize a remarkably different set of antigens. In a way, one 
can say that it is surprising that their identification has taken so long. Interestingly enough, 
though, researchers were already studying part of this cell population when focusing on 
circulating CD161-expressing CD8+ T cells in a wide variety of contexts. Given the novelty 
of these cells and the immense progress that has been made in a short period of time, one can 
only look forward in anticipation to the coming years of MAIT cell research. 
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